

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61K 31/70, 31/715, 39/00	A1	(11) International Publication Number: WO 91/19501 (43) International Publication Date: 26 December 1991 (26.12.91)
(21) International Application Number: PCT/US91/03592 (22) International Filing Date: 22 May 1991 (22.05.91) (30) Priority data: 538,853 15 June 1990 (15.06.90) US 619,319 28 November 1990 (28.11.90) US 632,390 21 December 1990 (21.12.90) US (71) Applicant: CYTEL CORPORATION [US/US]; 11099 North Torrey Pines Road, Suite 100, La Jolla, CA 92037 (US). (72) Inventors: PAULSON, James, C. ; 15255 Del Gado, Sher- man Oaks, CA 91403 (US). PEREZ, Mary, S. ; 3525 Hastings Drive, Carlsbad, CA 92008 (US). GAETA, Federico, C., A. ; 8126 Camino del Sol, La Jolla, CA 92037 (US).		(74) Agent: SMITH, William, M.; Townsend and Townsend, One Market Plaza, 2000 Steuart Tower, San Francisco, CA 94105 (US). (81) Designated States: AT, AT (European patent), AU, BB, BE (European patent), BF (OAPI patent), BG, BJ (OAPI patent), BR, CA, CF (OAPI patent), CG (OAPI patent), CH, CH (European patent), CI (OAPI patent), CM (OAPI patent), DE, DE (European patent), DK, DK (European patent), ES, ES (European patent), FI, FR (European patent), GA (OAPI patent), GB, GB (Euro- pean patent), GR (European patent), HU, IT (European patent), JP, KP, KR, LK, LU, LU (European patent), MC, MG, ML (OAPI patent), MR (OAPI patent), MW, NL, NL (European patent), NO, PL, RO, SD, SE, SE (European patent), SN (OAPI patent), SU, TD (OAPI patent), TG (OAPI patent). Published <i>With international search report.</i>
(54) Title: INTERCELLULAR ADHESION MEDIATORS (57) Abstract Novel selectin ligands have been identified and various uses for the ligands and antibodies reactive thereto are provided, including targeted delivery of liposome formulations.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TC	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark				

WO 91/19501

PCT/US91/03592

1

INTERCELLULAR ADHESION MEDIATORS

5

FIELD OF THE INVENTION

The present invention relates to compositions and methods for reducing or controlling inflammation and for treating inflammatory disease processes and other pathological conditions mediated by intercellular adhesion.

10

BACKGROUND OF THE INVENTION

Vascular endothelial cells and blood platelets play key roles in a number of biological responses by selectively binding certain cells, for instance phagocytic leukocytes, in the blood stream. For example, endothelial cells preferentially bind monocytes and granulocytes prior to their migration through the blood vessel wall and into surrounding tissue in an inflammatory response. Certain inflammation-triggering compounds are known to act directly on the vascular endothelium to promote the adhesion of leukocytes to vessel walls, which cells then move through the walls and into areas of injury or infection. Cellular adhesion to vascular endothelium is also thought to be involved in tumor metastasis.

Circulating cancer cells apparently take advantage of the body's normal inflammatory mechanisms and bind to areas of blood vessel walls where the endothelium is activated.

Blood platelets are also involved in similar responses. Platelets are known to become activated during the initiation of hemostasis and undergo major morphological, biochemical, and functional changes (e.g., rapid granule exocytosis, or degranulation), in which the platelet alpha granule membrane becomes fused with the external plasma membrane. As a result, new cell surface proteins become expressed that confer on the activated platelet new functions, such as the ability to bind both other activated platelets and other cells. Activated platelets are recruited into growing thrombi or are cleared rapidly from the blood circulation.

35

WO 91/19501

PCT/US91/03592

2

Activated platelets are known to bind to phagocytic leukocytes, including monocytes and neutrophils. Examples of pathological and other biological processes which are thought to be mediated by this process include atherosclerosis, blood clotting and inflammation.

Recent work has revealed that specialized cell surface receptors on endothelial cells and platelets, designated endothelial leukocyte adhesion molecule-1 (ELAM-1) and granule membrane protein-140 (GMP-140), respectively, are involved in the recognition of various circulating cells by the endothelium and platelets. These receptors are surface glycoproteins with a lectin-like domain, a region with homology to epidermal growth factor, and a region with homology to complement regulatory proteins (see, Bevilacqua et al., Science 243:1160 (1989), which is incorporated herein by reference). For example, ELAM-1 has been shown to mediate endothelial leukocyte adhesion, which is the first step in many inflammatory responses. Specifically, ELAM-1 binds human neutrophils, monocytes, eosinophils, certain T-lymphocytes (N. Graber et al., J. Immunol., 145:819 (1990)), NK cells, and the promyelocytic cell line HL-60.

The term "selectin" has been suggested for a general class of receptors, which includes ELAM-1 and GMP-140, because of their lectin-like domain and the selective nature of their adhesive functions. These cell surface receptors are expressed on a variety of cells. GMP-140 (also known as PADGEM) is present on the surface of platelets and endothelial cells, where it mediates platelet-leukocyte and endothelium-leukocyte interactions. Another member of the selectin class is the MEL-14 antigen and its human analog LAM-1 which are cell surface receptors of lymphocytes, and act as lymph node homing receptors. The exact nature of the ligand recognized by selectin receptors, however, has remained largely unknown.

Various other methods have been previously developed to block the action of selectins and thus inhibit cellular adhesion. For instance, the use of monoclonal antibodies directed to ELAM-1 has been proposed as a method to inhibit endothelial-leukocyte adhesion as a treatment for pathological

WO 91/19501

PCT/US91/03592

3

responses, such as inflammation. Endothelial interleukin-8 has also been shown to be an inhibitor of leukocyte-endothelial interactions.

With the elucidation of the ligand-receptor interaction it will be possible to develop highly specific, efficient inhibitors of selectin-mediated cellular adhesion which would be useful in therapeutic regimens. The ligand(s) could also be used to target other pharmaceutical compounds, such as anti-inflammatory agents or anti-oxidants, to the sites of injury. To date, however, insufficient understanding of the interaction of the ligand(s) and receptor molecules on the respective cells has hindered these efforts. The present invention fulfills these and other related needs.

15 SUMMARY OF THE INVENTION

Novel compositions which selectively bind a selectin cell surface receptor and which have at least one oligosaccharide moiety are provided by the present invention. The compositions inhibit intercellular adhesion mediated by the selectin cell surface receptor and thereby are capable, for example, of inhibiting inflammatory and other pathological responses associated with cellular adhesion. Generally, the composition comprises sialic acid and fucose, a sulfate, or a phosphate. In related embodiments the composition that binds the selectin may be a glycoprotein, a glycolipid, or an oligosaccharide.

In one aspect, pharmaceutical compositions are provided. The pharmaceutical compositions can be, for example, liposomes which comprise a ligand oligosaccharide moiety capable of selectively binding a selectin receptor and a pharmaceutically acceptable carrier. The liposome containing the ligand may also serve as a targeting vehicle for a conventional chemotherapeutic agent, which agent is contained within the liposome and delivered to targeted cells which express a selectin receptor. Typically the chemotherapeutic agent is an anti-inflammatory agent or an anti-oxidant. Using the ligands described herein to target chemical agents encapsulated within liposomes is a convenient and effective

WO 91/19501

PCT/US91/03592

4

method for reducing therapeutic levels of a drug and minimizing side effects.

In other aspects, the invention comprises methods of inhibiting intercellular adhesion in a patient for a disease process such as inflammation or reperfusion injury by administering to the patient a therapeutically effective dose of a compound comprising a moiety capable of binding a selectin cell surface receptor. The cell surface receptor, such as ELAM-1 or GMP-140, may be expressed on vascular endothelial cells or platelets. The inflammatory process may be, for example, rheumatoid arthritis. The compound which is administered may have an oligosaccharide moiety having the chemical formula: $\text{NeuAc}\alpha 2,3\text{Gal}\beta 1,4(\text{Fuc}\alpha 1,3)\text{GlcNAc}\beta 1\text{-R}_1$; wherein R_1 is an amino acid, oligopeptide, lipid, or oligosaccharide.

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 illustrates the ability of cells which express SLX (LEC 11) to bind to IL-1 β activated endothelial cells compared to those cells which express non-sialylated Le^x (CHO-K1 and LEC 12).

Fig. 2 illustrates the ability of monoclonal antibodies specific for SLX to block selectin-mediated binding of HL-60 cells at 37°C (Fig. 2A) and 4°C (Fig. 2B) compared to monoclonal antibodies which do not bind SLX determinants.

Fig. 3 illustrates the effects of incubating LEC 11 (Fig. 3A) and LEC 12 (Fig. 3B) cells with SLX and non-SLX specific monoclonal antibodies on binding to activated endothelial cells.

Fig. 4 illustrates the results obtained by treating HL-60, LEC11 and LEC12 cells with sialidase before binding to activated endothelial cells.

Fig. 5 compares the ability of liposomes which contain glycolipids with SLX, Le^x, or similar carbohydrate structures to inhibit the binding of HL-60 cells to activated endothelial cells.

WO 91/19501

PCT/US91/03592

5

Fig. 6 compares the inhibition of GMP-140 mediated platelet adhesion by monoclonal antibodies specific for SLX and Le^x determinants.

Fig. 7 compares the ability of liposomes which
5 contain glycolipids with SLX, Le^x, or similar carbohydrate structures to inhibit the binding of HL-60 cells to activated platelets.

Fig. 8 compares the ability of liposomes which
contain glycolipids with SLX, Le^x, or similar carbohydrate
10 structures to inhibit the binding of PMNs to activated platelets.

Fig. 9 shows inhibition of GMP-140 mediated adhesion by glycolipids with the terminal sialic acid either NeuAc or NeuGc.

15

DESCRIPTION OF THE PREFERRED EMBODIMENT

Compositions and methods are provided for inhibiting inflammatory and other disease responses mediated by cellular adhesion. The present invention also provides compounds (e.g.,
20 glycoconjugates and monoclonal antibodies) which have the ability to block or inhibit the adhesion of the cells mediated by selectin cell surface receptors. Methods for preparing and screening for such compounds are also provided. In addition, diagnostic and therapeutic uses for the compounds are provided.

25 A basis of the present invention is the discovery of a carbohydrate moiety recognized by selectin cell surface receptors. As discussed above, selectins, also known as the "LEC-CAM" family of cell adhesion molecules, are unique glycoproteins expressed on the surface of a variety of cells.
30 For instance, ELAM-1 is inducibly expressed on vascular endothelial cells (Bevilacqua et al., supra and Hession et al., Proc. Nat'l. Acad. Sci., 87:1673-1677 (1990), both of which are incorporated herein by reference). This receptor has been demonstrated to be induced by inflammatory cytokines such as
35 interleukin I β (IL-I β) and tumor necrosis factor α (TNF α), as well as bacterial endotoxin (lipopolysaccharide) (see, Bevilacqua et al., Proc. Natl. Acad. Sci., 84:9238-9242 (1987) which is incorporated herein by reference). These compounds

WO 91/19501

PCT/US91/03592

6

act directly on endothelial cells in vitro to substantially augment polymorphonuclear leukocyte (neutrophil), and monocyte adhesion (Bevilacqua et al., Proc. Natl. Acad. Sci., supra).

As discussed above, GMP-140 is a membrane glycoprotein of platelet and endothelial secretory granules (Geng et al., Nature, 343, 757-760 (1990) which is incorporated herein by reference). Activated platelets which express GMP-140 on their surface are known to bind to monocytes and neutrophils (Jungi et al., Blood 67:629-636 (1986)), and also to monocyte-like cell lines, e.g., HL60 and U937 (Jungi et al., supra; Silverstein et al., J. Clin. Invest. 79:867-874 (1987)), all of which are incorporated herein by reference. GMP-140 is an alpha granule membrane protein of molecular weight 140,000 that is expressed on the surface of activated platelets upon platelet stimulation and granule secretion (Hsu-Lin et al., J. Biol. Chem. 259:9121-9126 (1984); Stenberg et al., J. Cell Biol. 101:880-886 (1985); Berman et al., J. Clin. Invest. 78:130-137 (1986)). It is also found in megakaryocytes (Beckstead et al., Blood 67:285-293 (1986)), and in endothelial cells (McEver et al., Blood 70:355a (1987)) within the Weibel-Palade bodies (Bonfanti et al., Blood 73:1109-1112 (1989)). Furie et al. U.S. Patent No. 4,783,330, describe monoclonal antibodies reactive with GPM-140. All of the foregoing references are incorporated herein by reference.

A third selectin receptor is the lymphocyte homing receptor, MEL-14 antigen or LAM-1 (Gallatin et al., Nature 304:30-34 (1983); Siegelman et al., Science, 243:1165-1172 (1989); Rosen, Cell Biology, 1:913-919 (1989); and Lasky et al. Cell 56:1045-1055 (1989) all of which are incorporated herein by reference). In addition to lymphocyte homing, MEL-14 antigen/LAM-1 is believed to function early in neutrophil binding to the endothelium.

The structure and function of selectin receptors has been elucidated by cloning and expression of full length cDNA encoding each of the above receptors (see, e.g., Bevilacqua et al., Science, supra, (ELAM-1), Geng et al., supra, (GMP 140), and Lasky et al., supra, (MEL-14 antigen)). The extracellular portion of selectins can be divided into three segments based

WO 91/19501

PCT/US91/03592

7

on homologies to previously described proteins. The N-terminal region (about 120 amino acids) is related to the C-type mammalian lectin protein family as described by Drickamer, J. Biol. Chem., 263: 9557-9560 (1988) (which is incorporated
5 herein by reference) that includes low affinity IgE receptor CD23. A polypeptide segment follows, which has a sequence that is related to proteins containing the epidermal growth factor (EGF) motif. Lastly, after the EGF domain are one or more
10 tandem repetitive motifs of about 60 amino acids each, related to those found in a family of complement regulatory proteins.

Since selectin receptors comprise a lectin-like domain, the specificity of the molecules is likely to be based on protein-carbohydrate interactions. Evidence provided here indicates that a sialylated, fucosylated N-acetylglucosamine
15 unit of the Lewis X antigen, designated here as SLX, is a moiety recognized by the lectin region of the selectin receptor. In particular, the evidence shows recognition of this moiety by both ELAM-1 and GMP-140. Compounds of the present invention comprise this fucosylated, sialylated N-
20 acetylglucosamine unit in a variety of configurations.

The nomenclature used to describe the oligosaccharide moieties of the present invention follows the conventional nomenclature. Standard abbreviations for individual
monosaccharides are used. For instance, 2-N-acetylglucosamine
25 is represented by GlcNAc, fucose is Fuc, galactose is Gal, and glucose is Glc. Two sialic acids which may be present on the oligosaccharides of the present invention are 5-N-acetylneuraminic acid (NeuAc) and 5-N-glycolylneuraminic acid (NeuGc). Unless otherwise indicated, all sugars except fucose
30 (L-isomer) are D-isomers in the cyclic pyranose configuration. The two anomers of the cyclic forms are represented by α and β .

The monosaccharides are generally linked by glycosidic bonds to form oligo- and polysaccharides. The orientation of the bond with respect to the plane of the rings
35 is indicated by α and β . The particular carbon atoms that form the bond between the two monosaccharides are also noted. Thus, a β glycosidic bond between C-1 of galactose and C-4 of glucose is represented by Gal β 1,4Glc. For the D-sugars (e.g., D-

WO 91/19501

PCT/US91/03592

8

GlcNAc, D-Gal, and D-NeuAc) the designation α means the hydroxyl attached to C-1 (C-2 in NeuAc) is below the plane of the ring and β is above the ring. In the case of L-fucose, the α designation means the hydroxyl is above the ring and β means it is below.


Having identified SLX as a carbohydrate ligand that mediates leukocyte-endothelial and leukocyte-platelet cell adhesion, compounds comprising SLX or its mimetics can be purified or synthesized de novo. Once obtained, such compounds can be used for a variety of purposes, including, for example, competitive inhibition of the binding of SLX-bearing cells to cells which express the selectin receptors. By binding of the compounds of the invention to a cell surface selectin, interaction of the selectin with the native SLX ligand on migrating cells will be prevented, interfering with normal and pathological binding of leukocytes and other cells to the endothelium or platelets. Thus, compounds which contain one or more SLX-R units or mimetics can serve as effective inhibitors of, for instance, inflammation, atherosclerosis, clotting and other endothelial or platelet-mediated pathologies.

Compounds containing SLX can be obtained from the cell surface glycoproteins or glycolipids from a number of cells. For instance, the SLX antigen is present on N-linked carbohydrate groups of the cell surface glycoproteins of LEC11 cells, a glycosylation mutant of CHO cells. LEC11 expresses this unique glycopeptide which contains a terminal structure bearing both sialic acid and fucose in the SLX sequence:

WO 91/19501


PCT/US91/03592

9



5 (SLX-R)

where R is:



(See, Stanley et al., J. Biol. Chem., 263:11374 (1988), which
 15 is incorporated herein by reference.) Using the procedure
 described below, it was demonstrated that the LEC11 mutant
 bound to activated human vascular endothelial cells. Neither
 wild type CHO cells nor other related glycosylation mutant CHO
 cell lines without the particular glycosylation pattern (SLX)
 20 showed the same level of binding.

In the SLX moiety expressed by LEC11 cells, the
 sialic acid is in the form of NeuAc. The sialic acid may be in
 other forms, such as NeuGc, without significantly affecting
 binding. For instance, SLX isolated from bovine erythrocytes
 25 comprises NeuGc. As demonstrated in Example IX, below, the
 affinity for selectin receptors is the same for both forms.
 Thus, the term "SLX" as used herein refers to the minimal
 tetrasaccharide unit shown above in which the terminal sialic
 acid is NeuAc, NeuGc or other equivalent forms of sialic acid.
 30 Structures illustrated herein which show the sialic acid
 residue as NeuAc are understood to include these other forms,
 in particular NeuGc.

Naturally occurring variations on the basic SLX moiety
 are also recognized by selectin receptors. For instance,
 35 evidence provided in Example VIII, below, shows that an
 oligosaccharide moiety, termed SY2 (also known as the VIM
 antigen), having the structure

$$\text{NeuGc}\alpha 2,3\text{Gal}\beta 1,4\text{GlcNAc}\beta 1,3\text{Gal}\beta 1,4(\text{Fuc}\alpha 1,3)\text{GlcNAc}\beta 1,3\text{Gal}\beta 1,4\text{Glc}\beta$$

WO 91/19501

PCT/US91/03592

10

binds selectin receptors as well as SLX. The SY2 moiety comprises two sialylated N-acetyllactosamine units, one of which is SLX. Thus, oligosaccharides recognized by selectin receptors may comprise a number of the sialylated N-

5 acetyllactosamine units, at least one of which is fucosylated (see, Teimeyer et al., Proc. Natl. Acad. Sci. (USA) 88:1138-1142 (1991), which is incorporated herein by reference.

Sources that can be used to obtain the SLX unit include any cell which naturally expresses the moiety on

10 glycolipid or glycoprotein carbohydrate groups. Thus, polymorphonuclear neutrophils, lymphocytes, tumor cells or HL-60 cells have been used to purify this unit. Other cells which bind to activated vascular endothelium can also be used to isolate the ligand (see, Symington et al., J. Immunol.

15 134:2498-2506 (1985), Mizoguchi et al., J. Biol. Chem. 259:11949-11957 (1984), Mizoguchi et al., J. Biol. Chem. 259:11943-11948 (1984), Paietta et al., Cancer Res. 48:28-287 (1988), all of which are incorporated herein by reference).

Compounds containing SLX or its mimetics can be

20 prepared from natural sources using methods well known in the art for isolating surface glycoproteins, glycopeptides, oligosaccharides and glycolipids from cells (See, e.g., Gerard, "Purification of glycoproteins" and Thomas et al., "Purification of membrane proteins," both in Guide to Protein

25 Purification, Vol. 182, Methods in Enzymology (Deutscher ed., 1990), which is incorporated herein by reference). For example, LEC11 cells can be used to obtain glycoprotein or glycolipid which contains the SLX unit using, for instance, the method described in Stanley et al., supra. Briefly, in one

30 method LEC11 cells are infected with vesicular stomatitis virus. The structural carbohydrate alterations exhibited by LEC11 are then expressed on the N-linked biantennary carbohydrates of the G glycoprotein of the virus. The virus is purified by equilibrium gradient centrifugation, and

35 glycopeptides are purified using proteinase digestion as described by Stanley et al.

Several approaches are used to isolate a selectin-binding moiety from HL-60, HT-29, colo 205, neutrophils, and

WO 91/19501

PCT/US91/03592

11

other cell lines which contain a ligand recognized by selectins. Since the ligand is generally expressed on the cell surface of these cell types, one approach consists of isolating a plasma membrane fraction enriched in the ligand. Once plasma
5 membranes have been isolated, the ligands may be isolated and subsequently identified using monoclonal antibodies, particularly those which are reactive with the SLX oligosaccharide structure, such as monoclonal antibodies FH6, SNH3 and CSLEX-1.

10 To characterize a selectin ligand, release of the oligosaccharide from the glycopeptide is generally the first step in the structural analysis of the oligosaccharide chain. This is accomplished by chemical cleavage of the protein-carbohydrate linkage, or by specifically releasing the
15 oligosaccharide with endoglycosidases. In most cases, different procedures may be used to establish the correct conditions for an individual glycoprotein. Asparagine-linked oligosaccharides are released by hydrazinolysis, endoglycosidases, vigorous alkaline hydrolysis, and
20 trifluoroacetolysis. O-linked carbohydrate units are released by alkaline β -elimination. The oligosaccharides are separated from the glycopeptides by gel filtration. The resulting oligosaccharides are then separated from each other using a combination of gel filtration, HPLC, thin layer chromatography,
25 and ion exchange chromatography. The isolated oligosaccharides are then fully analyzed. Complete structural analysis of the purified oligosaccharide units requires the determination of the monosaccharide units, their ring form, configuration (D or L), anomeric linkage (α or β), the positions of the linkages
30 between the sugars and their sequence. In addition, the position of any substituent groups are established. Methylation analysis is used to determine the positions of the glycosidic linkages between the monosaccharides. The anomeric configuration of the sugar residues can be addressed using 500-
35 MHz ^1H NMR spectroscopy. The conditions and methods used to perform a complete structural carbohydrate analysis are described generally in Beeley, Laboratory Techniques in Biochemistry and Molecular Biology, eds. Burdon and

WO 91/19501

PCT/US91/03592

12

Knippenberg, Elsevier, Amsterdam (1985), incorporated herein by reference.

The state of the art techniques to fully characterize the sugars of an oligosaccharide include the use of several analytical techniques such as FAB-MS (fast atom bombardment-mass spectrometry), HPAE (high pH anion exchange chromatography) and ¹H-NMR. These techniques are complementary. Recent examples of how these techniques are used to fully characterize the structure of an oligosaccharide can be found in the analysis by Spellman et al., J. Biol. Chem. 264:14100 (1989), and Stanley et al., supra. Other methods include positive ion fast atom bombardment mass spectroscopy (FAB-MS) and methylation analysis by gas chromatography - electron impact mass spectroscopy (GC/EI-MS) (see, EPO Application No. 89305153.2, which is incorporated herein by reference).

One approach to characterizing the selectin ligand on glycolipids consists of disrupting the cells using organic solvents, isolating the glycolipids, and identifying those glycolipids reactive with monoclonal antibodies to SLX, such as FH6, SNH3, SNH4, CSLEX-1, or VIM-2, for example, and then determining the structure of the oligosaccharide chains. To obtain glycolipids and gangliosides which contain SLX, standard methods for glycolipid preparation can be used (see, e.g., Ledeen et al., J. Neurochem. 21:829 (1973), which is incorporated herein by reference). For example, glycolipids are extracted from HL-60, HT-29, PMNs, human leukocytes, and other cell lines expressing the selectin ligand by methods generally known to those skilled in the arts (see, e.g., Symington et al., J. Immunol. 134:2498 (1985) and Macher and Beckstead, Leukemia Res. 14:119-130 (1990)). Cells are grown in suspension and are harvested by centrifugation. Glycolipids are extracted from the cell pellet by chloroform/methanol 2:1 and isopropyl alcohol/hexane/water 55:25:20 as described by Kannagi et al., J. Biol. Chem. 257:14865 (1982). The resulting extracts are partitioned by a chloroform/methanol/water (3:2:1) Folch partition. The resulting upper phase of the extraction contains gangliosides and the lower phase contains glycolipids.

WO 91/19501

PCT/US91/03592

13

The upper phase containing gangliosides (glycosphingolipids that contain at least one sialic acid moiety) are isolated and separated into neutral and acidic fractions using DEAE-Sephadex chromatography as described in detail by Ledeen and Yu, Methods Enzymol. 83:139 (1982). The resulting gangliosides are pooled, lyophilized, and dissolved in chloroform/methanol (2:1). The lower phase of the Folch partition contains glycolipids. These are isolated and separated on preparative thin-layer chromatography using chloroform/methanol/water (60:35:8) as the solvent system as described by Symington.

To identify those gangliosides and glycolipids which contain the selectin ligand, immunochemical glycolipid analysis is performed according to the procedure of Magnani et al., Anal. Biochem. 109:399 (1980). Briefly, the ganglioside pool described above is chromatographed by thin layer chromatography. The thin layer plate is then incubated with ¹²⁵I labeled FH6, or other monoclonal antibody which binds specifically to SLX. Following incubation with the labeled antibody, the plate is exposed to radiographic detection film and developed. Black spots on the X-ray film correspond to gangliosides that bind to the monoclonal antibody, and those gangliosides are recovered by scraping the corresponding areas of the silica plate and eluting the gangliosides with chloroform/methanol/water. Glycolipids are also dried and resuspended in chloroform and developed in a similar thin layer system and probed with the radiolabeled antibody. Structural analysis of oligosaccharides derived from glycolipids is performed essentially as described for glycoproteins.

Oligosaccharides comprising the SLX unit can be prepared from glycoproteins by methods well known in the art (see, e.g., Gerard, supra, at pp. 537-539). Typically, N-glycosidase F (N-glycanase) is used to cleave N-linked oligosaccharides while O-linked groups are cleaved with endo-N-acetylgalactosaminidase.

Synthetic compounds containing SLX or its mimetics attached to a variety of moieties can be prepared depending on the particular use desired. For example, SLX can be converted

WO 91/19501

PCT/US91/03592

14

to a ganglioside by linking a ceramide moiety to the C-1 of the reducing terminal GlcNAc unit. SLX structures can also be linked to a wide variety of other moieties such as variously substituted amino groups, heterocyclic compounds, ether

5 linkages with branched or unbranched carbon chains, and ether linkages with aryl or alkylaryl moieties. The SLX unit may also be bound to various amino acids, amino acid mimetics, oligopeptides or proteins.

The term "alkyl" as used herein means a branched or


10 unbranched saturated or unsaturated hydrocarbon chain, including lower alkyls of 1-7 carbons such as methyl, ethyl, n-propyl, butyl, n-hexyl, and the like, cycloalkyls (3-7 carbons), cycloalkylmethyls (4-8 carbons), and arylalkyls. The term "aryl" refers to a radical derived from an aromatic

15 hydrocarbon by the removal of one atom, e.g., phenyl from benzene. The aromatic hydrocarbon may have more than one unsaturated carbon ring, e.g., naphthyl. "Heterocyclic compounds" refers to ring compounds having three or more atoms in which at least one of the atoms is other than carbon (e.g.,

20 N, O, S, Se, P, or As). Examples of such compounds include furans, pyrimidines, purines, pyrazines and the like.

For the synthesis of polyvalent forms of SLX, monomeric units containing SLX can be joined to form molecules having one to about four or more SLX moieties. An example of

25 such a polyvalent form is one in which the oligosaccharide units are linked by the following moieties:




wherein, n and m are the same or different and are integers from 2 to 12; Y is O or S; and W is O, S, or NH; or

WO 91/19501

PCT/US91/03592

15



wherein, Z is a 5- to 14-membered ring and the substituents on
5 the ring are in a cis- or trans-relationship, and the
substituents are in a 1,2 to 1,(p/2)+1 arrangement, where p is
the size of the ring. If the ring is a heterocyclic ring
(e.g., one comprising nitrogen atoms) the oligosaccharide
moieties are preferably linked to the nitrogen atoms on the
10 ring. Examples of heterocyclic compounds that are suitable for
this purpose include piperazine and homopiperazine.

Alternatively, polyvalent forms of SLX or its
mimetics can be created by attaching the desired moiety to
preformed carrier moieties with multiple sites of attachment.
15 Examples include attachment of SLX to the amino groups of
lysine and lysine-containing peptides, proteins, glycoproteins
or the asparagine side-chain of such compounds.

One method of preparing polyvalent forms of SLX is
by addition of desired monosaccharide residues to
20 polysaccharides. For instance, the conversion of a
polysaccharide which contains the linear core structure of SLX
into a polyvalent SLX containing polysaccharide is achieved by
enzymatic fucosylation. Native polysaccharide type Ia obtained
from Group B Streptococcus is preferably used. The entire
25 200,000 dalton polysaccharide can be used for this purpose as
well as fragments thereof. Thus, polysaccharides having a
molecular weight between about 5,000 and about 300,000 can be
used. A molecular weight between about 25,000 and about
100,000 is preferred. Any number of side chains on the
30 polysaccharide type Ia may be fucosylated for the
polysaccharide to have activity. Typically, between about 5
and about 200 side chains are fucosylated, preferably between
about 50 and about 150 are fucosylated.


The synthesis of the SLX moiety can be accomplished
35 using chemical, enzymatic, or combined chemical and enzymatic
strategies. (see, e.g., EPO Publication No. 319,253, which is
incorporated herein by reference.) In a preferred method
(Scheme I below), a compound containing one or more N-
acetylglucosamine units (GlcNAc-R) can be reacted sequentially

WO 91/19501

PCT/US91/03592

16

with a galactosyltransferase (N-acetylglucosamine β 1,4 galactosyltransferase (E.C. 2.4.1.90)), a sialyltransferase (Gal β 1,4GlcNAc α 2,3 sialyltransferase (E.C. 2.4.99.6) or Gal β 1,3GalNAc α 2,3 sialyltransferase (E.C. 2.4.99.4) and a fucosyltransferase (N-acetylglucosaminide α 1,3 fucosyltransferase (E.C. 2.4.1.152)) to yield the final SLX-containing structures. In this case, R may be a carrier moiety or activatable intermediate that will allow attachment to a suitable carrier moiety. Each enzymatic reaction uses the appropriate nucleotide sugar as a donor substrate to generate the following intermediates in the synthesis of SLX. The glycosyl transfer reactions may optimally be carried out with added alkaline phosphatase (e.g., from calf intestine, CIAP) to consume the nucleoside phosphate byproduct which may inhibit the reaction.



Scheme I

The general conditions for preparative enzymatic synthesis of carbohydrate groups analogous to SLX are known (see, e.g., Toone *et al.*, *Tetrahedron* 45:5365-5422 (1989); Wong *et al.*, *J. Am. Chem. Soc.* 47:5416-5418 (1982); Unverzagt *et al.*, *J. Am. Chem. Soc.* 112:9308-9309 (1990); Prieels *et al.*, *J. Biol. Chem.* 256:10456-10463 (1981), all of which are incorporated herein by reference). Each of the key enzymatic reactions has been demonstrated (Beyer *et al.*, *Adv. Enzymol.*

WO 91/19501

PCT/US91/03592

17

52:23-176 (1981); Toone et al., supra; and Howard et al., J. Biol. Chem. 262:16830-16837 (1981); all of which are incorporated herein by reference). For preparative reactions, the galactosyltransferase and the sialyltransferase(s) are
5 purified from natural sources (Beyer et al., supra, and Weinstein et al., J. Biol. Chem. 257:13835-13844 (1982), which are incorporated herein by reference). Fucosyltransferases may also be identified from natural sources, as generally described in Crawley and Hindsgaul, Carbohydr. Res. 193:249-256 (1989),
10 incorporated by reference herein. The cDNAs of the galactosyltransferase and a sialyltransferase have been cloned (Paulson and Colley, J. Biol. Chem. 264:17615-17618 (1989), which is incorporated herein by reference), allowing the production of soluble recombinant enzymes for large-scale
15 preparative synthesis (Colley et al., J. Biol. Chem. 264:17619-17622 (1989)).

To obtain sufficient amounts of fucosyltransferase for large-scale reaction, the enzyme can be cloned and expressed as a recombinant soluble enzyme by someone with
20 ordinary skill in the art. As a preferred method RNA can be subtracted from the wild type CHO cells and LEC11 cells as described by Chirgwin et al., Biochemistry 18:5214-5299 (1979), and the poly A+ RNA isolated by chromatography on oligo(dT)-cellulose. Next, cDNA from the LEC-11 cells can be prepared as
25 described by Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Ed. (1989), Cold Spring Harbor Press, New York, which is incorporated herein by reference. The cDNA can be subtracted using the method of Davis (Handbook of Experimental Immunology, Vol. 2, pp. 1-13 (1986)) using excess poly A+ RNA
30 from wild type CHO cells, which do not express the desired fucosyltransferase, but otherwise have most of the mRNA species of LEC11 cells. A cDNA library can then be constructed in the CDM8 expression vector using the subtracted cDNA (Seed, Nature 329:840-842 (1987)). Clones expressing the
35 fucosyltransferase can be isolated using the expression cloning method described by Larsen et al., Proc. Natl. Acad. Sci. 86:8227-8231 (1989), employing transfection of COS-1 cells and screening for cells expressing the SLX antigen with the FH6

WO 91/19501

PCT/US91/03592

18

antibody or other antibody with specificity for the SLX antigen. The full-length clone of the fucosyltransferase can then be used to produce a soluble recombinant enzyme as taught by Colley et al., supra.


- 5 Another source of SLX is α_1 -acid glycoprotein, which is a plasma glycoprotein, the carbohydrate moities of which can be fucosylated to produce SLX (see, Alpha,-Acid glycoprotein: Genetics, Biochemistry, Physiological Functions, and Pharmacology, Bauman et al. ed. (Wiley 1989), and Walz, et al. 10 Science 250:1132-1135 (1990), both of which are incorporated herein by reference).

Although enzymatic or combined chemical and enzymatic synthesis of SLX compounds are preferred, chemical synthesis is also possible, as shown in Schemes II and IIa below.

WO 91/19501

PCT/US91/03592

19




Scheme II

WO 91/19501

20

PCT/US91/03592



Scheme IIa

WO 91/19501

PCT/US91/03592

21

Component pieces of the SLX structure have been synthesized. Nicolaou, et al., (J. Amer. Chem. Soc. 112:3693 (1990)) have published the total synthesis of the tumor-associated Le^x family of glycosphingolipids. Therein is described the synthesis of the protected trisaccharide Gal β 1,4(Fuc α 1,3)GlcNAc (A). Reaction of this intermediate with an appropriate glycosyl acceptor (e.g., an alcohol moiety) results in compound (B). Selective deprotection and acetylation of the glucosamine moiety are carried out essentially as described in Nicolaou, et al. to afford compound (C). Reaction of (C) with a sialyltransferase as described above furnishes the desired product SLX-R, although this may be produced in relatively low yield using Scheme II.

Modified fucosides may be included in the synthetic schemes to provide for SLX analogues which vary in this moiety. For example, α -D-arabinosyl glycosides may be synthesized following known procedures, Nicolaou et al., J. Amer. Chem. Soc. 112:3693-3695 (1990) through the use of tri-O-benzyl arabinosyl halides. Other C-5 aryl or alkyl substituted arabinosyl moieties may be synthesized, Danishefsky et al., J. Amer. Chem. Soc. 107:1274 (1985), Danishefsky, Aldrichimica Acta. 19:59-68 (1986) and references therein, and introduced into the disaccharide in the same manner. All of these references are incorporated herein by reference.

According to alternative Scheme IIa, the trisaccharide (A) is partially deprotected to furnish (D), which is subsequently reacted with the peracetylated sialic acid methyl ester (E) following a procedure described by Kameyama et al., XV Intl. Carbohydr. Symp., Abst. No. A096, (1990), and Carbohydrate Res., 209:c1-c4 (1991) (which are incorporated herein by reference), yielding (F) after chromatographic purification. Treatment of (F) sequentially with methylhydrazine, N-acetylation, O-deacetylation and ester hydrolysis furnishes SLX-R.

Preferred examples of R for scheme II and IIa include alkyl (straight chain, branched, saturated, mono- and poly-unsaturated); serine (D or L); serine containing peptides; di- and tri-alkanolamines (e.g. $[\text{HO}(\text{CH}_2)_n]_2\text{NH}$, $[\text{HO}(\text{CH}_2)_n]_3\text{N}$; wherein

WO 91/19501

PCT/US91/03592

22

n = C₂-C₂₀ as straight chain, branched, unsaturated, mono- and poly-unsaturated). R can also be aryl, substituted aryl (e.g., Me, OH, I; alone or in combination including ¹²⁵I), alkylaryl, arylalkyl or other moiety, as the skilled artisan would include
5 for the desired use. The introduction of iodine into phenolic compounds such as tyrosine is known in the art. Radical groups containing phenols are useful for the introduction of ¹²⁵I radioisotope, yielding compounds which are useful in diagnosis.

The SLX ligand as disclosed here may also be used to
10 assay for the presence of compounds which are capable of inhibiting intercellular adhesion mediated by selectins. A number of methods can be used to assay the biological activity of test compounds for the ability to inhibit the selectin-mediated response. Ideally, the assays of the present
15 invention allow large scale in vitro or in vivo screening of a variety of compounds.

The agent or test compound to be screened will typically be a synthetic or naturally-produced biomolecule, such as a peptide, polypeptide, protein (e.g., monoclonal
20 antibody), carbohydrate (e.g., oligosaccharide), glycoconjugate, nucleic acid, and the like. The compounds are synthetically produced using, for instance, the methods for synthesizing oligosaccharides described above (see, also, Khadem, Carbohydrate Chemistry (Academic Press, San Diego, CA,
25 1988), which is incorporated herein by reference). Methods for synthesizing polypeptides of defined composition are well known in the art (see, Atherton et al. Solid Phase Peptide Synthesis (IRL Press, Oxford, 1989) which is incorporated herein by reference). If the synthetic test compounds are polymeric
30 (e.g., polypeptides or polysaccharides) they are preferably altered in a systematic way to identify the sequence of monomers which have the desired effect (see, e.g., U.S. Patent No. 4,833,092, which is incorporated herein by reference).
Test compounds may also be isolated from any natural source,
35 such as animal, plant, fungal, or bacterial cells in accordance with standard procedures as described above. Potentially useful monoclonal antibodies can be prepared according to standard methods described in more detail, below.

WO 91/19501

PCT/US91/03592

23

The assays of the present invention are particularly useful in identifying compounds which act as antagonists or agonists of a ligand molecule. Antagonists are compounds which reverse the physiological effect of a ligand or exclude binding of the ligand to the receptor. An antagonist usually competes directly or indirectly with the ligand for the receptor binding site and, thus, reduces the proportion of ligand molecules bound to the receptor. Typically, an antagonist will be the topographical equivalent of the natural ligand and will compete directly with the ligand for the binding site on the selectin. Such a compound is referred to here as a "mimetic." An SLX mimetic is a molecule that conformationally and functionally serves as substitute for an SLX moiety in that it is recognized by a selectin receptor. Alternatively, if the ligand and the test compound can bind the receptor simultaneously, the compound may act non-competitively. A non-competitive inhibitor acts by decreasing or inhibiting the subsequent physiological effects of receptor-ligand interactions rather than by diminishing the proportion of ligand molecules bound to the receptor. Finally, the assays of the present invention can be used to identify synthetic or naturally occurring agonists, that is, compounds which bind the receptor and initiate a physiological response similar to that of the natural ligand.

Numerous direct and indirect methods for in vitro screening of inhibitors of ligand-receptor interactions are available and known to those skilled in the art. For instance, the ability to inhibit adhesion of SLX-bearing cells to cells expressing a particular selectin can be determined. As discussed above, selectin receptor genes have been cloned, thus the genes can be inserted and expressed in a wide variety of cells, such as COS cells, CHO cells and the like. In addition, cells which do not normally express SLX are capable of being transformed with one or more glycosyltransferase genes which confer on the transformed cells the ability to synthesize the ligand. (see, e.g., Lowe et al., Cell 63:475-484 (1990), which is incorporated herein by reference.) Typically, the test compound or agent is incubated with labelled SLX-bearing cells and activated endothelial cells immobilized on a solid surface.

WO 91/19501

PCT/US91/03592

24

Inhibition of cellular adhesion is then determined by detecting label bound to the surface after appropriate washes. In an exemplified assay described below, promyelocytic HL-60 cells and activated human endothelial cells or activated platelets are used.

Since a ligand specific for selectin receptors has now been identified, isolated ligand molecules can also be used in the assays. The terms "isolated selectin-binding agent" or "isolated SLX moiety" as used herein refer to a selectin binding or SLX-bearing compound that is in other than its native state, e.g., not associated with the cell membrane of a cell that normally expresses the ligand. Thus, an isolated SLX moiety may be a component of an isolated molecule, such as an oligosaccharide or a glycoconjugate. The isolated molecule may be synthesized or prepared from the membranes of SLX-bearing cells. Alternatively, the isolated selectin-binding agent or SLX moiety may be associated with a liposome or attached to a solid surface before use in the assay. Methods for preparing SLX-bearing liposomes and for immobilizing various biomolecules are extensively discussed below.

Typically, the in vitro assays of the present invention are competition assays which detect the ability of a test compound to competitively inhibit binding of a compound known to bind either the receptor or the ligand. Inhibition of binding between SLX and a selectin receptor is usually tested. Inhibition of other binding interactions are also suitable, for instance, inhibition of the binding between a monoclonal antibody (e.g., FH6) and SLX or between an SLX mimetic and a selectin inhibitor can be used. Numerous types of competitive assays are known (see, e.g., U.S. Patents No. 3,376,110, 4,016,043, and Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Publications, N.Y. (1988), which are incorporated herein by reference).

The assays of the present invention are also suitable for measuring binding of a test compound to one component alone rather than using a competition assay. For instance, immunoglobulins can be used to identify compounds that contain the SLX moiety. Standard procedures for monoclonal antibody

WO 91/19501

PCT/US91/03592

25

assays, such as ELISA, may be used (see, Harlow and Lane, supra). When assaying for glycolipids comprising the SLX antigen, the reactivity of the monoclonal antibody with the antigen can be assayed by TLC immunostaining by the method originally described in Magnani et al., Anal. Biochem. 109:399-402 (1980) or by solid-phase radioimmunoassay as described by Kanagi et al., Cancer Res. 43:4997-5005 (1983); which are incorporated herein by reference. Glycoproteins can be assayed by standard immunoblotting procedures as described in Harlow and Lane, supra. Sandwich assay formats are also suitable (see, e.g., U.S. Patent Nos. 4,642,285; 4,299,916; and 4,391,904; and Harlow and Lane, supra all of which are incorporated herein by reference). Typically, compounds which have been identified in a binding assay will be further tested to determine their ability to inhibit receptor-ligand interactions.

Other assay formats involve the detection of the presence or absence of various physiological changes in either ligand-bearing or selectin-bearing cells that result from the interaction. Examples of suitable assays include the measurement of changes in transcription activity induced by binding (see, e.g., EPO Publication No. 3712820), the detection of various cell mediated extra-cellular effects (see, e.g., PCT Publication No. 90/00503), and the detection of changes in the membrane potential of individual cells (see, e.g., U.S. Patent No. 4,343,782), all of which are incorporated herein by reference. Alternatively, conformational changes in isolated receptors or ligands can be detected; see, e.g., U.S. Patent No. 4,859,609, which is incorporated herein by reference.

Any component of the assay, including the ligand, the receptor, or the test compound, may be bound to a solid surface. Many methods for immobilizing biomolecules on solid surfaces are known in the art. For instance, the solid surface may be a membrane (e.g., nitrocellulose), a microtiter dish (e.g., PVC or polystyrene) or a bead. The desired component may be covalently bound or noncovalently attached through unspecific bonding.

WO 91/19501

PCT/US91/03592

26

A wide variety of organic and inorganic polymers, both natural and synthetic may be employed as the material for the solid surface. Illustrative polymers include polyethylene, polypropylene, poly(4-methylbutene), polystyrene, polymethacrylate, poly(ethylene terephthalate), rayon, nylon, poly(vinyl butyrate), silicones, polyformaldehyde, cellulose, cellulose acetate, nitrocellulose, etc. Other materials which may be employed, include paper, glasses, ceramics, metals, metalloids, semiconductive materials, cermets or the like. In addition are included substances that form gels, such as proteins, e.g., gelatins, lipopolysaccharides, silicates, agarose and polyacrylamides or polymers which form several aqueous phases, such as dextrans, polyalkylene glycols (alkylene of 2 to 3 carbon atoms) or surfactants e.g. amphiphilic compounds, such as phospholipids, long chain (12-24 carbon atoms) alkyl ammonium salts and the like. Where the solid surface is porous, various pore sizes may be employed depending upon the nature of the system.

In preparing the surface, a plurality of different materials may be employed, particularly as laminates, to obtain various properties. For example, protein coatings, such as gelatin can be employed to avoid non-specific binding, simplify covalent conjugation, enhance signal detection or the like.

If covalent bonding between a compound and the surface is desired, the surface will usually be polyfunctional or be capable of being polyfunctionalized. Functional groups which may be present on the surface and used for linking can include carboxylic acids, aldehydes, amino groups, cyano groups, ethylenic groups, hydroxyl groups, mercapto groups and the like. The manner of linking a wide variety of compounds to various surfaces is well known and is amply illustrated in the literature. See for example Immobilized Enzymes, Ichiro Chibata, Halsted Press, New York, 1978, and Cuatrecasas, J. Biol. Chem. 245 3059 (1970) which is incorporated herein by reference.

In addition to covalent bonding, various methods for noncovalently binding an assay component can be used. Noncovalent binding is typically nonspecific absorption of a

WO 91/19501

PCT/US91/03592

27

compound to the surface. Typically, the surface is blocked with a second compound to prevent nonspecific binding of labelled assay components. Alternatively, the surface is designed such that it nonspecifically binds one component but
5 does not significantly bind another. For example, a surface bearing a lectin such as Concanavalin A will bind a carbohydrate containing compound but not a labelled protein that lacks glycosylation. Various solid surfaces for use in noncovalent attachment of assay components are reviewed in U.S.
10 Patent Nos. 4,447,576 and 4,254,082, which are incorporated herein by reference.

Many assay formats employ labelled assay components such as SLX ligands, SLX mimetics, immunoglobulins, receptors, or test compounds. The label may be coupled directly or
15 indirectly to the desired component of the assay according to methods well known in the art. A wide variety of labels may be used. The component may be labelled by any one of several methods. The most common method of detection is the use of autoradiography with ^3H , ^{125}I , ^{35}S , ^{14}C , or ^{32}P labelled compounds
20 or the like. The choice of radioactive isotope depends on research preferences due to ease of synthesis, varying stability, and half lives of the selected isotopes. Other non-radioactive labels include ligands which bind to labelled antibodies, fluorophores, chemiluminescent agents, enzymes, and
25 antibodies which can serve as specific binding pair members for a labelled ligand. The choice of label depends on sensitivity required, ease of conjugation with the compound, stability requirements, and available instrumentation.

Non-radioactive labels are often attached by indirect
30 means. Generally, a ligand molecule (e.g., biotin) is covalently bound to the molecule. The ligand then binds to an anti-ligand (e.g., streptavidin) molecule which is either inherently detectable or covalently bound to a signal system, such as a detectable enzyme, a fluorescent compound, or a
35 chemiluminescent compound. Ligands and anti-ligands may be varied widely. Where a ligand has a natural anti-ligand, for example, biotin, thyroxine, and cortisol, it can be used in conjunction with the labelled, naturally occurring anti-

WO 91/19501

PCT/US91/03592

28

ligands. Alternatively, any haptenic or antigenic compound can be used in combination with an antibody.

The molecules can also be conjugated directly to signal generating compounds, e.g., by conjugation with an enzyme or fluorophore. Enzymes of interest as labels will primarily be hydrolases, particularly phosphatases, esterases and glycosidases, or oxidoreductases, particularly peroxidases. Fluorescent compounds include fluorescein and its derivatives, rhodamine and its derivatives, dansyl, umbelliferone, etc. Chemiluminescent compounds include luciferin, and 2,3-dihydrophthalazinediones, e.g., luminol. For a review of various signal producing systems which may be used, see, U.S. Patent No. 4,391,904, which is incorporated herein by reference.

As discussed above, in addition to various inhibitor compounds which comprise an accessible SLX unit or SLX mimetic, the present invention also provides monoclonal antibodies capable of inhibiting intercellular adhesion mediated by selectins as well as methods for identifying such antibodies. The monoclonal antibodies bind a selectin ligand or receptor and block cellular adhesion. Thus, the multitude of techniques available to those skilled in the art for production and manipulation of various immunoglobulin molecules can be applied to inhibit intercellular adhesion.

As used herein, the term "immunoglobulin" refers to a protein consisting of one or more polypeptides substantially encoded by immunoglobulin genes. The recognized immunoglobulin genes include the kappa, lambda, alpha, gamma, delta, epsilon and mu constant region genes, as well as the myriad immunoglobulin variable region genes. The immunoglobulins may exist in a variety of forms besides antibodies, including for example, Fv, Fab, and F(ab)₂, as well as in single chains (e.g., Huston et al., Proc. Nat. Acad. Sci. U.S.A. 85:5879-5883 (1988) and Bird et al., Science 242:423-426 (1988), which are incorporated herein by reference). (see, generally, Hood et al., Immunology, 2nd ed., Benjamin, N.Y. (1984), and Hunkapiller and Hood, Nature 323:15-16 (1986), which are incorporated herein by reference.)

WO 91/19501

PCT/US91/03592

29

Antibodies which bind the SLX antigen may be produced by a variety of means. The production of non-human monoclonal antibodies, e.g., murine, lagomorpha, equine, etc., is well known and may be accomplished by, for example, immunizing the animal with the SLX antigen or a preparation containing a glycoprotein or glycolipid comprising the antigen. Antibody-producing cells obtained from the immunized animals are immortalized and screened, or screened first for the production of antibody which inhibits the interaction of the viral surface protein with the receptor molecule and then immortalized. For a discussion of general procedures of monoclonal antibody production see Harlow and Lane, Antibodies, A Laboratory Manual (1988), supra.

The generation of human monoclonal antibodies to a human antigen (in the case of an SLX unit isolated from human tissue) may be difficult with conventional techniques. Thus, it may be desirable to transfer the antigen binding regions of the non-human antibodies, e.g., the F(ab')₂ or hypervariable regions, to human constant regions (Fc) or framework regions by recombinant DNA techniques to produce substantially human molecules. Such methods are generally known in the art and are described in, for example, U.S. 4,816,397, EP publications 173,494 and 239,400, which are incorporated herein by reference. Alternatively, one may isolate DNA sequences which encode a human monoclonal antibody or portions thereof that specifically bind to the human SLX by screening a DNA library from human B cells according to the general protocol outlined by Huse et al., Science 246:1275-1281 (1989), incorporated herein by reference, and then cloning and amplifying the sequences which encode the antibody (or binding fragment) of the desired specificity.

A number of currently available monoclonal antibodies can be used according to the present invention to inhibit intercellular adhesion mediated by selectins. For instance, CSLEX-1 (see, Campbell et al., J. Biol. Chem. 259:11208-11214 (1984)), VIM-2, which recognizes a sequence slightly different from SLX (see, Macher et al., supra), FH6 (described in U.S. Patent No. 4,904,596) (all references are incorporated herein

WO 91/19501

PCT/US91/03592

30

by reference) or SH₃ and SH₄ generated by Dr. S. Hakomori of the Biomembrane Institute in Seattle, Washington.

The compounds of the present invention, including immunoglobulins, can be used in preparing pharmaceutical formulations as discussed below. If the compound is an oligosaccharide or glycoconjugate, the SLX or SLX-mimetic moiety can be presented in a variety of forms, but should be able to effectively bind to a selectin receptor, such as ELAM-1, GMP-140, or MEL-14 antigen and thereby inhibit intercellular adhesion.

The pharmaceutical compositions of the present invention can be used to block or inhibit cellular adhesion associated with a number of disorders. For instance, a number of inflammatory disorders are associated with selectins expressed on vascular endothelial cells and platelets. The term "inflammation" is used here to refer to reactions of both the specific and non-specific defense systems. A specific defense system reaction is a specific immune system reaction to an antigen. Example of specific defense system reactions include antibody response to antigens, such as viruses, and delayed-type hypersensitivity. A non-specific defense system reaction is an inflammatory response mediated by leukocytes generally incapable of immunological memory. Such cells include macrophages, eosinophils and neutrophils. Examples of non-specific reactions include the immediate swelling after a bee sting, and the collection of PMN leukocytes at sites of bacterial infection (e.g., pulmonary infiltrates in bacterial pneumonias and pus formation in abscesses).

Other treatable disorders include, e.g., rheumatoid arthritis, post-ischemic leukocyte-mediated tissue damage (reperfusion injury), frost-bite injury or shock, acute leukocyte-mediated lung injury (e.g., adult respiratory distress syndrome), asthma, traumatic shock, septic shock, nephritis, and acute and chronic inflammation, including atopic dermatitis, psoriasis, and inflammatory bowel disease. Various platelet-mediated pathologies such as atherosclerosis and clotting can also be treated. In addition, tumor metastasis can be inhibited or prevented by inhibiting the adhesion of

WO 91/19501

PCT/US91/03592

31

circulating cancer cells. Examples include carcinoma of the colon and melanoma.

By way of example, reperfusion injury is particularly amenable to treatment by compositions of the present invention.

5 Compositions which inhibit a GMP-140 selectin-ligand interaction may be particularly useful for treating or preventing reperfusion injury. The present invention may be used prophylactically prior to heart surgery to enhance post-surgical recovery.

10 Because GMP-140 is stored in Weibel-Palade bodies of platelets and endothelial cells and is released upon activation by thrombin to mediate adhesion of neutrophils and monocytes, inhibitors of the GMP-140 -ligand interaction may be especially useful in minimizing tissue damage which often accompanies
15 thrombotic disorders. For instance, such inhibitors may be of therapeutic value in patients who have recently experienced stroke, myocardial infarctions, deep vein thrombosis, pulmonary embolism, etc. The compounds are especially useful in pre-thrombolytic therapy.

20 Compositions of the invention find particular use in treating the secondary effects of septic shock or disseminated intravascular coagulation (DIC). Leukocyte emigration into tissues during septic shock or DIC often results in pathological tissue destruction. Furthermore, these patients
25 may have widespread microcirculatory thrombi and diffuse inflammation. The therapeutic compositions provided herein inhibit leukocyte emigration at these sites and mitigates tissue damage.

The inhibitors of selectin-ligand interaction also
30 are useful in treating traumatic shock and acute tissue injury associated therewith. Because the selectins play a role in recruitment of leukocytes to the sites of injury, particularly ELAM-1 in cases of acute injury and inflammation, inhibitors thereof may be administered locally or systemically to control
35 tissue damage associated with such injuries. Moreover, because of the specificity of such inhibitors for sites of inflammation, e.g., where ELAM-1 receptors are expressed, these compositions will be more effective and less likely to cause

WO 91/19501

PCT/US91/03592

32

complications when compared to traditional anti-inflammatory agents.

Thus, the present invention also provides pharmaceutical compositions which can be used in treating the
5 aforementioned conditions. The pharmaceutical compositions are comprised of biomolecules or other compounds which comprise an SLX unit, antibodies which bind to SLX, or other compounds which inhibit the interaction between the SLX ligand and selectin receptors, together with pharmaceutically effective
10 carriers. A biomolecule of the present invention may be a peptide, polypeptide, protein (e.g., an immunoglobulin), carbohydrate (e.g., oligosaccharide or polysaccharide), glycoconjugate (e.g., glycolipid or glycoprotein), nucleic acid, and the like. The pharmaceutical compositions are
15 suitable for use in a variety of drug delivery systems. For a brief review of present methods for drug delivery, see, Langer, Science 249:1527-1533 (1990), which is incorporated herein by reference.

In light of the complexity of the inflammatory
20 response in mammals, one of skill will readily recognize that the pharmaceutical compositions of the present invention may comprise SLX bearing compounds in admixture with other compounds known to interfere with the function of other cellular adhesion molecules. For instance, members of the
25 integrin family of adhesion molecules are thought to play a role in the extravasation of leukocytes at points of infection. For a review of intercellular adhesion receptors, including selectin receptors, and their role immune function, see Springer, Nature 346:425-434 (1990), which is incorporated
30 herein by reference. In addition, successful treatment using the pharmaceutical compositions of the present invention may also be determined by the state of development of the condition to be treated. Since different adhesion molecules may be up or down regulated in response to a variety of factors during the
35 course of the disease or condition, one of skill will recognize that different pharmaceutical compositions may be required for treatment of different inflammatory states.

WO 91/19501

PCT/US91/03592

33

In one embodiment, the SLX ligand of the pharmaceutical composition can be used to target conventional anti-inflammatory drugs or other agents to specific sites of tissue injury. By using a selectin-binding oligosaccharide moiety such as an SLX ligand or SLX mimetic to target a drug to a selectin receptor on, e.g., a vascular endothelial cell, such drugs can achieve higher concentrations at sites of injury. Side effects from the conventional anti-inflammatory chemotherapeutic agents can be substantially alleviated by the lower dosages, the localization of the agent at the injury sites and/or the encapsulation of the agent prior to delivery.

The targeting component, i.e., the SLX ligand or an SLX mimetic which binds to a desired selectin, can be directly or indirectly coupled to the chemotherapeutic agent. The coupling, which may be performed by means, generally known in the art, should not substantially inhibit the ability of the ligand to bind the receptor nor should it substantially reduce the activity of the chemotherapeutic agent. A variety of chemotherapeutics can be coupled for targeting. For example, anti-inflammatory agents which may be coupled include SLX-bearing compounds of the present invention, immunomodulators, platelet activating factor (PAF) antagonists, cyclooxygenase inhibitors, lipoxxygenase inhibitors, and leukotriene antagonists. Some preferred moieties include cyclosporin A, indomethacin, naproxen, FK-506, mycophenolic acid, etc. Similarly, anti-oxidants, e.g., superoxide dismutase, are useful in treating reperfusion injury when targeted by a SLX ligand or mimetic. Likewise, anticancer agents can be targeted by coupling the SLX ligand or mimetic to the chemotherapeutic agent. Examples of agents which may be coupled include daunomycin, doxorubicin, vinblastine, bleomycin, etc.

The selectin receptor targeting may also be accomplished via amphipaths, or dual character molecules (polar:nonpolar) which exist as aggregates in aqueous solution. Amphipaths include nonpolar lipids, polar lipids, mono- and diglycerides, sulfatides, lysolecithin, phospholipids, saponin, bile acids and salts. These molecules can exist as emulsions and foams, micelles, insoluble monolayers, liquid crystals,

WO 91/19501

PCT/US91/03592

34

phospholipid dispersions and lamellar layers. These are generically referred to herein as liposomes. In these preparations the drug to be delivered is incorporated as part of a liposome in conjunction with a SLX ligand or mimetic which binds to the selectin receptor. Thus, liposomes filled with a desired chemotherapeutic agent can be directed to a site of tissue injury by the selectin-SLX ligand interaction. When the liposomes are brought into proximity of the affected cells, they deliver the selected therapeutic compositions.

The liposomes of the present invention are formed from standard vesicle-forming lipids, which generally include neutral and negatively charged phospholipids and a sterol, such as cholesterol. The selection of lipids is generally guided by consideration of, e.g., liposome size and stability of the liposomes in the bloodstream.

Typically, the major lipid component in the liposomes is phosphatidylcholine. Phosphatidylcholines having a variety of acyl chain groups of varying chain length and degree of saturation are available or may be isolated or synthesized by well-known techniques. In general, less saturated phosphatidylcholines are more easily sized, particularly when the liposomes must be sized below about 0.3 microns, for purposes of filter sterilization. Methods used in sizing and filter-sterilizing liposomes are discussed below. The acyl chain composition of phospholipid may also affect the stability of liposomes in the blood. One preferred phosphatidylcholine is partially hydrogenated egg phosphatidylcholine.

Targeting of liposomes using a variety of targeting agents (e.g., ligands, receptors and monoclonal antibodies) is well known in the art. (see, e.g., U.S. Patent Nos. 4,957,773 and 4,603,044, both of which are incorporated herein by reference). Glycoproteins and glycolipids of a variety of molecular weights can be used as targeting agents. Typically, glycoproteins having a molecular weight less than about 300,000 daltons, preferably between about 40,000 and about 250,000 are used, more preferably between about 75,000 and about 150,000. Glycolipids of molecular weight of less than about 10,000 daltons, preferably between about 600 and about 4,000 are used.

WO 91/19501

PCT/US91/03592

35

Standard methods for coupling targeting agents to liposomes can be used. These methods generally involve incorporation into liposomes of lipid components, such as phosphatidylethanolamine, which can be activated for attachment of targeting agents, or derivatized lipophilic compounds, such as lipid derivatized bleomycin.. Antibody targeted liposomes can be constructed using, for instance, liposomes which incorporate protein A (see, Renneisen, et al., J. Biol. Chem., 265:16337-16342 (1990) and Leonetti et al., Proc. Natl. Acad. Sci. (USA) 87:2448-2451 (1990), both of which are incorporated herein by reference).

Targeting mechanisms generally require that the targeting agents be positioned on the surface of the liposome in such a manner that the target agents are available for interaction with the selectin receptor. The liposome is typically fashioned in such a way that a connector portion is first incorporated into the membrane at the time of forming the membrane. The connector portion must have a lipophilic portion which is firmly embedded and anchored in the membrane. It must also have a hydrophilic portion which is chemically available on the aqueous surface of the liposome. The hydrophilic portion is selected so that it will be chemically suitable to form a stable chemical bond with the targeting agent which is added later. Therefore, the connector molecule must have both a lipophilic anchor and a hydrophilic reactive group suitable for reacting with the target agent and holding the target agent in its correct position, extended out from the liposome's surface. In some cases it is possible to attach the target agent to the connector molecule directly, but in most instances it is more suitable to use a third molecule to act as a chemical bridge, thus linking the connector molecule which is in the membrane with the target agent which is extended, three dimensionally, off of the vesicle surface.

Liposome charge is an important determinant in liposome clearance from the blood, with negatively charged liposomes being taken up more rapidly by the reticuloendothelial system (Juliano, Biochem. Biophys. Res. Commun. 63:651 (1975)) and thus having shorter half-lives in

WO 91/19501

PCT/US91/03592

36

the bloodstream. Liposomes with prolonged circulation half-lives are typically desirable for therapeutic and diagnostic uses. Liposomes which can be maintained from 8, 12, or up to 24 hours in the bloodstream provide sustained release of the
5 selectin-ligand inhibitors of the invention, or may facilitate targeting of the inhibitors (which may be labelled to provide for in vivo diagnostic imaging) to a desired site before being removed by the reticuloendothelial system.

Typically, the liposomes are prepared with about 5-15
10 mole percent negatively charged phospholipids, such as phosphatidylglycerol, phosphatidylserine or phosphatidylinositol. Added negatively charged phospholipids, such as phosphatidylglycerol, also serves to prevent spontaneous liposome aggregating, and thus minimize the risk of
15 undersized liposomal aggregate formation. Membrane-rigidifying agents, such as sphingomyelin or a saturated neutral phospholipid, at a concentration of at least about 50 mole percent, and 5-15 mole percent of monosialylganglioside, may provide increased circulation of the liposome preparation in
20 the bloodstream, as generally described in U.S. Pat. No. 4, 837,028, incorporated herein by reference.

Additionally, the liposome suspension may include lipid-protective agents which protect lipids and drug components against free-radical and lipid-peroxidative damages
25 on storage. Lipophilic free-radical quenchers, such as alphanatocopherol and water-soluble iron-specific chelators, such as ferrioxianine, are preferred.

A variety of methods are available for preparing liposomes, as described in, e.g., Szoka et al., Ann. Rev. Biophys. Bioeng. 9:467 (1980), U.S. Pat. Nos. 4, 235,871,
30 4,501,728 and 4,837,028, incorporated herein by reference. One method produces multilamellar vesicles of heterogeneous sizes. In this method, the vesicle forming lipids are dissolved in a suitable organic solvent or solvent system and dried under
35 vacuum or an inert gas to form a thin lipid film. If desired, the film may be redissolved in a suitable solvent, such as tertiary butanol, and then lyophilized to form a more homogeneous lipid mixture which is in a more easily hydrated

WO 91/19501

PCT/US91/03592

37

powder-like form. This film is covered with an aqueous solution of the targeted drug and the targeting component and allowed to hydrate, typically over a 15-60 minute period with agitation. The size distribution of the resulting

5 multilamellar vesicles can be shifted toward smaller sizes by hydrating the lipids under more vigorous agitation conditions or by adding solubilizing detergents such as deoxycholate.

The hydration medium contains the targeted drug at a concentration which is desired in the interior volume of the

10 liposomes in the final liposome suspension. Typically the drug solution contains between 10-100 mg/ml in a buffered saline. The concentration of the targeting SLX molecule or mimetic which binds a selectin is generally between about 0.1 - 20 mg/ml.

15 Following liposome preparation, the liposomes may be sized to achieve a desired size range and relatively narrow distribution of liposome sizes. One preferred size range is about 0.2-0.4 microns, which allows the liposome suspension to be sterilized by filtration through a conventional filter,

20 typically a 0.22 micron filter. The filter sterilization method can be carried out on a high through-put basis if the liposomes have been sized down to about 0.2-0.4 microns.

Several techniques are available for sizing liposomes to a desired size. One sizing method is described in U.S. Pat.

25 No. 4,737,323, incorporated herein by reference. Sonicating a liposome suspension either by bath or probe sonication produces a progressive size reduction down to small unilamellar vesicles less than about 0.05 microns in size. Homogenization is another method which relies on shearing energy to fragment

30 large liposomes into smaller ones. In a typical homogenization procedure, multilamellar vesicles are recirculated through a standard emulsion homogenizer until selected liposome sizes, typically between about 0.1 and 0.5 microns, are observed. In both methods, the particle size distribution can be monitored

35 by conventional laser-beam particle size discrimination.

Extrusion of liposome through a small-pore polycarbonate membrane or an asymmetric ceramic membrane is also an effective method for reducing liposome sizes to a

WO 91/19501

PCT/US91/03592

38

relatively well-defined size distribution. Typically, the suspension is cycled through the membrane one or more times until the desired liposome size distribution is achieved. The liposomes may be extruded through successively smaller-pore membranes, to achieve a gradual reduction in liposome size.

Even under the most efficient encapsulation methods, the initial sized liposome suspension may contain up to 50% or more drug and targeting agent in free (non-encapsulated) form. Therefore, to maximize the advantages of liposomal targeted drug, it is important to remove free drug and targeting agent from the final injectable suspension.

Several methods are available for removing non-entrapped compound from a liposome suspension. In one method, the liposomes in the suspension are pelleted by high-speed centrifugation leaving free compound and very small liposomes in the supernatant. Another method involves concentrating the suspension by ultrafiltration, then resuspending the concentrated liposomes in a drug-free replacement medium. Alternatively, gel filtration can be used to separate large liposome particles from solute molecules.

Following treatment to remove free drug and/or targeting agent, the liposome suspension is brought to a desired concentration for use in intravenous administration. This may involve resuspending the liposomes in a suitable volume of injection medium, where the liposomes have been concentrated, for example by centrifugation or ultrafiltration, or concentrating the suspension, where the drug removal step has increased total suspension volume. The suspension is then sterilized by filtration as described above. The liposome-ligand preparation may be administered parenterally or locally in a dose which varies according to, e.g., the manner of administration, the drug being delivered, the particular disease being treated, etc.

For pharmaceutical compositions which comprise the SLX ligand, and/or SLX mimetics which bind to selectin receptors, the dose of the compound will vary according to, e.g., the particular compound, the manner of administration, the particular disease being treated and its severity, the

WO 91/19501

PCT/US91/03592

39

overall health and condition of the patient, and the judgment of the prescribing physician. For example, for the treatment of reperfusion injury, the dose is in the range of about 50 μ g to 2,000 mg/day for a 70 kg patient. Ideally, therapeutic administration should begin as soon as possible after the myocardial infarction or other injury. The pharmaceutical compositions are intended for parenteral, topical, oral or local administration, such as by aerosol or transdermally, for prophylactic and/or therapeutic treatment. The pharmaceutical compositions can be administered in a variety of unit dosage forms depending upon the method of administration. For example, unit dosage forms suitable for oral administration include powder, tablets, pills, capsules and dragees.

Preferably, the pharmaceutical compositions are administered intravenously. Thus, this invention provides compositions for intravenous administration which comprise a solution of the compound dissolved or suspended in a pharmaceutically acceptable carrier, preferably an aqueous carrier. A variety of aqueous carriers may be used, e.g., water, buffered water, 0.4% saline, and the like. These compositions may be sterilized by conventional, well known sterilization techniques, or may be sterile filtered. The resulting aqueous solutions may be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile aqueous solution prior to administration. The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions, such as pH adjusting and buffering agents, tonicity adjusting agents, wetting agents and the like, for example, sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, sorbitan monolaurate, triethanolamine oleate, etc.

The concentration of SLX ligand or mimetic, which may be combined with other SLX ligands or mimetics to form a "cocktail" for increased efficacy in the pharmaceutical formulation, can vary widely, i.e., from less than about 0.05%, usually at or at least about 1% to as much as 10 to 30% by weight and will be selected primarily by fluid volumes,

WO 91/19501

PCT/US91/03592

40

viscosities, etc., in accordance with the particular mode of administration selected. The cocktail may also comprise a monoclonal antibody which binds to selectin receptor, e.g., a monoclonal antibody to ELAM-1 or GMP-140, combined with the SLX ligand, a ligand mimetic or a monoclonal antibody to the ligand, so as to effectively inhibit the ligand-receptor interaction. As described above, the cocktail components may be delivered via liposome preparations.

Thus, a typical pharmaceutical composition for intravenous infusion could be made up to contain 250 ml of sterile Ringer's solution, and 25 mg of the compound. Actual methods for preparing parenterally administrable compounds will be known or apparent to those skilled in the art and are described in more detail in for example, Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, PA (1985), which is incorporated herein by reference.

For solid compositions, conventional nontoxic solid carriers may be used which include, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, magnesium carbonate, and the like. For oral administration, a pharmaceutically acceptable nontoxic composition is formed by incorporating any of the normally employed excipients, such as those carriers previously listed, and generally 10-95% of active ingredient, that is, one or more SLX ligands or mimetics of the invention, preferably about 20% (see, Remington's, supra).

For aerosol administration, the compounds are preferably supplied in finely divided form along with a surfactant and propellant. Typical percentages of SLX oligosaccharide ligands or mimetics are 0.05% - 30% by weight, preferably 1% - 10%. The surfactant must, of course, be nontoxic, and preferably soluble in the propellant. Representative of such agents are the esters or partial esters of fatty acids containing from 6 to 22 carbon atoms, such as caproic, octanoic, lauric, palmitic, stearic, linoleic, linolenic, olesteric and oleic acids with an aliphatic polyhydric alcohol or its cyclic anhydride such as, for

WO 91/19501

PCT/US91/03592

41

example, ethylene glycol, glycerol, erythritol, arabitol, mannitol, sorbitol, the hexitol anhydrides derived from sorbitol, and the polyoxyethylene and polyoxypropylene derivatives of these esters. Mixed esters, such as mixed or natural glycerides may be employed. The surfactant may constitute 0.1%-20% by weight of the composition, preferably 0.25-5%. The balance of the composition is ordinarily propellant. Liquefied propellants are typically gases at ambient conditions, and are condensed under pressure. Among suitable liquefied propellants are the lower alkanes containing up to 5 carbons, such as butane and propane; and preferably fluorinated or fluorochlorinated alkanes. Mixtures of the above may also be employed. In producing the aerosol, a container equipped with a suitable valve is filled with the appropriate propellant, containing the finely divided compounds and surfactant. The ingredients are thus maintained at an elevated pressure until released by action of the valve.

The compositions containing the compounds can be administered for prophylactic and/or therapeutic treatments. In therapeutic applications, compositions are administered to a patient already suffering from a disease, as described above, in an amount sufficient to cure or at least partially arrest the symptoms of the disease and its complications. An amount adequate to accomplish this is defined as "therapeutically effective dose." Amounts effective for this use will depend on the severity of the disease and the weight and general state of the patient, but generally range from about 0.5 mg to about 2,000 mg of SLX oligosaccharide or SLX mimetic per day for a 70 kg patient, with dosages of from about 5 mg to about 200 mg of the compounds per day being more commonly used.

In prophylactic applications, compositions containing the compounds of the invention are administered to a patient susceptible to or otherwise at risk of a particular disease. Such an amount is defined to be a "prophylactically effective dose." In this use, the precise amounts again depend on the patient's state of health and weight, but generally range from about 0.5 mg to about 1,000 mg per 70 kilogram patient, more

WO 91/19501

PCT/US91/03592

42

commonly from about 5 mg to about 200 mg per 70 kg of body weight.

Single or multiple administrations of the compositions can be carried out with dose levels and pattern being selected by the treating physician. In any event, the pharmaceutical formulations should provide a quantity of SLX oligosaccharide or SLX mimetic of this invention sufficient to effectively treat the patient.

The compounds may also find use as diagnostic reagents. For example, labeled compounds can be used to locate areas of inflammation or tumor metastasis in a patient suspected of having an inflammation. For this use, the compounds can be labeled with ^{125}I , ^{14}C , or tritium.

The following examples are offered by way of illustration, not by way of limitation.

EXAMPLE I

Isolation of $\alpha 1,3$ -fucosyltransferase I from Golgi Apparatus

LEC11, HL-60, HT-29, certain adenocarcinomas (colorectal cells in particular), and polymorphonuclear leukocytes (PMN, neutrophils) contain a very specific $\alpha 1,3$ -fucosyltransferase I, which is able to transfer fucose from GDP-fucose to the sialylated substrates NeuAc $\alpha 2,3$ Gal $\beta 1,4$ GlcNAc or NeuGc $\alpha 2,3$ Gal $\beta 1,4$ GlcNAc.

It is well known in the art that fucose is transferred to oligosaccharide chains in the lumen of the Golgi apparatus via specific fucosyltransferases, reviewed in Schacter and Roseman, in "The Biochemistry of Glycoproteins and Proteoglycans", W. Lennarz, ed., Plenum Press, New York, pp. 85-160 (1980), which is incorporated herein by reference. Since the subcellular localization of the fucosyltransferases is in the Golgi apparatus, the first step in the isolation of these enzymes is to isolate a Golgi apparatus fraction from a cell line which expresses this novel and specific $\alpha 1,3$ -fucosyltransferase.

Golgi apparatus-derived vesicle fractions are prepared by a modification of the procedure described by Balch et al., Cell, 39:405 (1984) which is incorporated herein by

WO 91/19501

PCT/US91/03592

43

reference. The LEC11, HL-60, HT-29, PMN, colo 205 or other cell lines containing the $\alpha 1,3$ -fucosyltransferase I are grown in suspension to a density of approximately 5×10^5 cells/ml. Cells are harvested from the suspension culture by

- 5 centrifugation at 2,000 X g. The resulting cell pellet from a 12 liter suspension (6×10^9 cells) is resuspended in 3 volumes (packed cell volume) of ice-cold 0.25M sucrose (w/v) solution containing Tris-Cl (10mM), pH 7.0, heat inactivated fetal calf serum (7%), and Aprotinin (100 μ g/ml, Sigma Chemical, Co. St.
10 Louis, Mo.).

- The cells are disrupted (approximately 60 strokes) with a tight fitting Wheaton glass dounce homogenizer using the A pestle. The homogenate is centrifuged for 5 min. at 500 X g in a table-top clinical centrifuge. Lipid and insoluble
15 material remaining at the top of the solution in the centrifuge tube is discarded. The cloudy supernatant is transferred to a clean tube, and the sucrose concentration of the supernatant fraction is then adjusted to 40% (w/v) sucrose in Tris-Cl (20 mM), pH 7.0, with the aid of a refractometer. Five milliliters
20 of this suspension is transferred to an ultracentrifuge tube and is layered sequentially with 2.5 ml of 35% (w/v) sucrose in Tris-Cl (10 mM, pH 7.0) and 2.0 ml of 29% (W/v) sucrose in 10 mM Tris-Cl buffer. The gradient is centrifuged for 1 hr. at 110,000 X g in a SW-41 rotor (Beckman) at 5°C. Golgi apparatus
25 enriched vesicles are collected from the 29% to 35% sucrose interphase. Other subcellular fractions are found at other interphases in the gradient; e.g., vesicles derived from the rough and smooth endoplasmic reticulum band below the Golgi derived vesicles, etc. The band removed from the 29% to 35%
30 interphase is analyzed for the presence and amount of sialyltransferase activity.

- The enzyme sialyltransferase is only known to be found within Golgi apparatus-derived vesicles and is used by those trained in the art as a marker to assess the authenticity of
35 the band collected from the 29-35% interphase. Sialyltransferase assays are performed using asialofetuin as the acceptor as described by Briles et al., J. Biol. Chem., 252:1107 (1977). A good Golgi apparatus derived vesicle

WO 91/19501

PCT/US91/03592

44

preparation from LEC cells typically has a sialyltransferase-specific activity of 3.0 nmole/mg protein/hr.

The resulting Golgi apparatus preparation is then used as a source of the $\alpha 1,3$ -fucosyltransferase I used in the enzymatic synthesis described above.

EXAMPLE II

Demonstration of Intercellular Adhesion by Cells Expressing SLX

The ability of LEC11 cells (which express SLX) to bind to activated endothelial cells expressing ELAM-1 was compared to that of CHO cells and another glycosylation mutant, LEC12, which expresses the structure Le^x, a non-sialylated form of SLX.

15

MATERIALS

Passage 5 human umbilical vein endothelial cells (HUVEC) (Clonetics) which had been grown on a gelatin coated 48 well assay plate were used as the source of endothelial cells. Cells were stimulated with IL-1 β (Genzyme) at 30 μ g/ml. Cells were stimulated for exactly 4 hrs. HL-60 cells provided by American Type Culture Collection (ATCC No. CCL 240) were used as the source of control ligand bearing cells. These were harvested from bulk culture in RPMI 1640 (Gibco) containing Penicillin (100 units/ml)/ Streptomycin (100 Mcg/ml) (Irvine Scientific), L-Glutamine (2mM) (Irvine Scientific) and 10% Fetal Bovine Serum (Hazleton) (hereafter referred to as CRPMI). LEC11, LEC12 and CHO-K1 were provided by Dr. P. Stanley. They were grown in suspension culture in complete alpha MEM containing ribonucleotides and deoxyribonucleotides (Gibco), Penicillin (100 units/ml)/ Streptomycin (100 μ g/ml) (Irvine Scientific), L-Glutamine (2mM) (Irvine Scientific) and 10% Fetal Bovine Serum (Hazelton).

PROCEDURE

1. HL-60, LEC11, LEC12 and CHO-K1 cells were harvested and washed in CRPMI. A viable cell count was made using trypan blue. 3×10^6 cells of each type were pelleted in

WO 91/19501

PCT/US91/03592

45

a 10 ml test tube and 300 μ l of ^{51}Cr (450 μCi) (New England Nuclear) was added to each pellet. The tubes were allowed to incubate 1 hour at 37°C with gentle agitation.

5 2. Labeled cells were washed 3X in medium and resuspended to 2×10^5 / 400 μ l (6ml). The tubes were then placed in a 4°C ice bath.

10 3. After 4 hours incubation with IL-1 β the assay plate containing activated HUVEC was removed from the incubator and chilled for 15 minutes by placing the plate in a 4°C ice bath.

15 4. When the temperature in both samples had equilibrated, the medium was removed from the assay wells with a pasteur pipette a few wells at a time.

20 5. Labeled cells were added to the wells in 400 μ l volumes equal to 2×10^5 cells/well. Three 400 μ l aliquots of each cell suspension were placed in glass tubes for determination of input CPMs.

25 6. The plate was incubated in the ice water bath for 30 minutes.

 7. Unbound cells were removed from the wells of the assay plate by systematic resuspension using a pasteur pipette followed by addition and removal of 0.7 ml of medium.

30 8. All of the medium was removed from the wells and a solution of 0.125 M Tris, 2% SDS and 10% glycerin was added (0.3 ml). The plate was allowed to stand for 30 minutes and then 0.5 ml of dH_2O was added to each well.

35 9. The fluid in each well was resuspended with a P1000 pipette and transferred to a glass test tube. The P1000 tip was ejected into the tube.

WO 91/19501

PCT/US91/03592

46

10. The tubes, including those containing the input CPM samples were counted in a gamma counter.

11. CPMs bound in each well were divided by the input CPMs for each sample to determine the % bound. The mean and standard deviation of triplicate assay points were plotted.

The results obtained in this experiment, shown in Fig. 1, indicate that cells expressing SLX have the ability to bind effectively to activated vascular endothelial cells expressing ELAM-1. These data show that LEC11 cells which express high levels of the unique carbohydrate SLX bind exceptionally well to IL-1 β activated HUVEC, while LEC12 and CHO-K1 which lack significant quantities of this carbohydrate are poor binders of the activated HUVEC. This conclusion is further supported by the observation that this binding occurs at 4°C, a characteristic of ELAM-1 mediated binding.

EXAMPLE III

Inhibition of Intercellular Adhesion by Monoclonal Antibodies Specific for SLX.

Two sets of experiments are described which confirm that the ligand on neutrophils for ELAM-1 contains an oligosaccharide where the terminal sugars are NeuAc α 2,3Gal β 1,4(Fuc α 1,3)GlcNac(SLX).

These experiments are performed by assaying the ability of monoclonal antibodies specific for sialylated Le^x and for the unsialylated form, Le^x, to block the ELAM-1 mediated adhesion of HL-60 cells to IL-1 β stimulated HUVEC.

A. Monoclonal Antibody Panel 1

Materials: Passage 3 HUVEC from cultures initiated for the present experiments were used as described above. Two sets of triplicate wells were left unstimulated as controls. Four triplicates were stimulated with IL-1 β (Genzyme) at 10 μ g/ml and 4 at 20 μ g/ml. Cells were stimulated for exactly 4 hours. HL-60 cells obtained from the American Type Culture Collection were used as the source of ligand bearing cells. These were harvested from bulk culture in RPMI-1640 (Gibco)

WO 91/19501

PCT/US91/03592

47

containing penicillin (100 units/ml), streptomycin (100 µg/ml) (Irvine Scientific), L-Glutamine (2mM) (Irvine Scientific) and 10% Fetal Bovine Serum (Hazleton) (hereafter referred to as CRPMI).

5 Monoclonal antibody preparations included SNH3 (IgM) at about 20 µg/ml and SH1 (IgG3) at about 10 µg/ml. The specificity of SNH3 is for SLX, while SH1 recognizes the unsialylated structure.

Procedure:

10 1. HL-60 cells were harvested and washed in CRPMI. A viable cell count was made using trypan blue. 3×10^6 cells were placed in each of 2, 10 ml test tubes and 300 µl of ^{51}Cr (450 µCi) (New England Nuclear) was added to each tube. The tubes were allowed to incubate 1 hour at 37°C with gentle
15 agitation.

2. The antibodies were supplied as hybridoma culture supernatants and contained 0.01% NaN₃ and 0.05% thimerosal. To remove these preservatives, 5 ml. of each
20 antibody was dialysed against 3 changes of 500 ml each of outdated tissue culture medium over 72 hours.

3. Antibodies were collected from dialysis and 3.5 ml of each was placed in 10 ml tubes. The remainder was
25 retained for use in an ELISA assay for HL-60 binding. 7 ml of RPMI 1640 5% FCS was placed in a 4th tube for use as a control.

4. Labeled HL-60 cells were washed 3X in CRPMI and pooled into one tube. They were then centrifuged and
30 resuspended to 1 ml in medium.

5. 200 µl of cell suspension was added to each of the antibody containing tubes and 400 µl to the control tube. Tubes were incubated 20 min. at 37°C with gentle agitation.

35

6. The stimulated HUVEC assay plate was removed from the incubator and the medium was removed from the wells with a pasteur pipette, a few wells at a time.

WO 91/19501

PCT/US91/03592

48

7. 0.5 ml of cell suspension was added to each of triplicate wells. Control cells were plated on unstimulated and stimulated HUVEC at both IL-1 β concentrations. Test cells
5 were added to stimulated wells only.

8. 0.5 ml aliquots of each cell suspension were added to glass tubes to be used to determine the input CPMs.

10 9. The assay plate was returned to the incubator (5% CO₂, 37°C) for 30 min.

10. An aliquot of each cell suspension was mixed with an equal volume of trypan blue and the cells were examined
15 microscopically for viability. The results were: Control = 98%, SH1 = 92%, and SNH3 = 99%.

11. Unbound cells were removed from the wells of the assay plate by systematic resuspension using a pasteur pipette
20 followed by addition and removal of 0.7 ml of medium.

12. All of the medium was removed from the wells and a solution of 0.125 M Tris, 2% SDS (Bio-Rad) and 10% glycerin (Fisher) was added (0.3 ml). The plates were allowed to stand
25 for 30 min. and then 0.6 ml of dH₂O was added to each well.

13. The fluid in each well was resuspended with a P1000 pipette and transferred to a glass test tube. The P1000 tip was ejected into the tube.
30

14. The tubes, including those containing the input counts per minute (CPM) samples were counted in a gamma counter.

35 15. CPMs bound in each well were divided by the input CPMs for each sample to determine the % bound. The mean and standard deviation of triplicate assay points were plotted.

WO 91/19501

PCT/US91/03592

49

Replicates were judged to be best in the experiment in which high IL-1 β was used to induce the endothelial cells.

The results showed that the monoclonal antibody SNH3 blocked the binding of HL-60 cells to IL-1 β stimulated HUVEC via the ELAM-1 receptor. The control antibody SH1 which does not bind the SLX determinant did not block binding of HL-60 cells to ELAM-1. This suggests that the terminal sialic acid in the ligand is necessary for binding to ELAM-1.

10 B. Monoclonal Antibody Panel 2

Materials: Passage 3 HUVEC which had been grown on gelatin coated 48 well assay plates (Costar) were used as the source of endothelial cells. The plates were prepared as previously described above. Two sets of triplicate wells were left unstimulated as controls. Seven triplicates on each plate were stimulated with IL-1 β at 30 μ g/ml in 0.5 ml of EGM-UV. Cells were stimulated for exactly 4 hrs. HL-60 cells (ATCC) were used as the source of ligand bearing cells. These were harvested from bulk culture in CRPMI. Fresh hybridoma supernatants containing monoclonal antibodies included: FH6 (IgM) a lower affinity mAb; SNH-3 (IgM) (20 μ g/ml); SH-1 (IgG₃) (10 μ g/ml); FH-2 (IgM) a Le^x reactive mAb; SNH-4 (IgG3) a high affinity antibody; and CSLEX-1 (IgM) (provided by Dr. P. Terasaki, UCLA as purified immunoglobulin at 2.8 mg/ml, diluted to 9 μ g/ml in Dulbecco's Modified Eagles Medium (DMEM) containing 5% FCS for use in this assay). The specificities of the antibodies were as follows: FH6, SNH-4, SNH3 and CSLEX-1 were specific for SLX; FH2 and SH1 were specific for the unsialylated Le^x.

30 Procedure:

1. HL-60 cells were harvested and washed in CRPMI. A viable cell count was made using trypan blue. 3 x 10⁶ cells were placed in each of 2, 10 ml test tubes and 300 μ l of ⁵¹Cr (450 μ Ci) (New England Nuclear) was added to each tube. The tubes were allowed to incubate 1 hour at 37°C with gentle agitation.

WO 91/19501

PCT/US91/03592

50

2. Labeled HL-60 cells were washed 3X in DMEM containing 5% FCS (hereafter referred to as cDMEM) and pooled into one tube. They were then centrifuged and resuspended to 4×10^6 cells per ml in the same medium.

5

3. 3.2 ml of each monoclonal antibody culture supernatant, and 3.2 ml purified CSLEX-1 (29 μ g), were added to separate test tubes; a control tube received 6.4 ml of medium.

10

4. 200 μ l of cell suspension (equal to about 8×10^5 cells) was added to tubes containing the monoclonal antibodies and 400 μ l to the control tube. Tubes were then incubated 20 min. at 37°C with gentle agitation.

15

5. The stimulated HUVEC assay plate was removed from the incubator and the wells were washed one time with cDMEM and the medium was removed from the wells with a pasteur pipette, a few wells at a time.

20

6. 0.4 ml of cell suspension was added to each well of one of the two plates. Control cells were plated on unstimulated and stimulated HUVEC. Antibody treated cells were added to stimulated wells only.

25

7. 0.4 ml aliquots of each cell suspension were added to glass tubes to be used to determine the input CPMS.

8. The assay plate was incubated at 37°C for 30 min.

30

9. The remainder of each cell suspension and the assay plate were placed in an ice bath to chill for 20 min.

35

10. The cell suspensions were plated on the chilled plate as for the 37°C plate above. This plate was incubated for 30 min. at 40°C.

WO 91/19501

PCT/US91/03592

51

The remaining steps of the assay were performed as described in steps 11-15 of Section A above, except that in step 12 the plates were allowed to stand for 15 min. rather than 30 min.

5 The results, shown in Fig. 2A, indicate that the monoclonal antibodies SNH-3, FH6, SNH-4 and CSLEX-1, all specific for SLX, significantly blocked the binding of HL-60 cells to IL-1 β stimulated HUVEC via the ELAM-1 receptor when incubated at 37°C. The monoclonal antibodies specific for Le^x (FH2 and SH1) were not effective inhibitors. Thus, the ligand for ELAM-1 contains the sialylated Le^x antigen or a similar structure found in cell surface glycoproteins or glycolipids.

10 When incubated at 4°C (Fig. 2B), antibodies FH6 and SNH-3 (both IgM's) enhanced binding. In these tests there appeared to be significant agglutination of the HL-60 cells in the wells, which may account for this observation.

C. Monoclonal Antibodies Block Adhesion of LEC11 Cells to Cells which Express ELAM-1

20 In this set of experiments the ability of monoclonal antibodies specific for SLX and for the unsialylated form, Le^x, to block the ELAM-1 mediated adhesion of LEC11 cells (which express SLX) and LEC12 cells (which express Le^x) to IL-1 β stimulated HUVEC.

25 Materials: Passage 4 HUVEC served as the source of endothelial cells. The plates were prepared as previously described. Two sets of triplicate wells were left unstimulated as controls. 7 triplicates on each plate were stimulated with IL-1 β at 30 μ g/ml in a 0.5 ml volume of EGM-UV. Cells were stimulated for exactly 4 hrs. LEC11 and LEC12 cells, described generally in Stanley et al., J. Biol. Chem., 263:11374 (1988), supra, were provided by Dr. P. Stanley. They were grown in suspension culture in complete alpha MEM containing ribonucleotides and deoxyribonucleotides (Gibco), penicillin (100 units/ml)/streptomycin (100 μ g/ml) (Irvine Scientific), L-Glutamine (2mM) (Irvine Scientific) and 10% FBS (Hazelton).

35 The monoclonal antibodies used in these experiments are

WO 91/19501

PCT/US91/03592

52

described in Section B, above. They included: FH6, SNH-3, SH-1, FH-2, SNH-4 and CSLEX-1.

Procedure:

- 5 1. LEC11 and LEC12 cells were harvested and washed in CRPMI. A viable cell count was made using trypan blue. 3×10^6 cells of each cell line were placed in each of 2, 10 ml test tubes and 300 μ l of ^{51}Cr (450 μCi) (New England Nuclear) was added to each tube. The tubes were allowed to incubate 1
10 hr. at 37°C with gentle agitation.
2. The radiolabeled cells were washed X3 in cDMEM and pooled into one tube. They were then centrifuged and resuspended to 4×10^6 cells per ml in the same medium.
15
3. 1.6 ml of each monoclonal antibody supernatant, and 1.6 ml purified CSLEX-1 (15 μg), were added to separate test tubes; control tubes received 3.2 ml medium.
- 20 4. 200 μ l of cell suspension equal to 4×10^5 LEC11 or LEC12 cells were added to tubes containing the monoclonal antibodies and 400 μ l to the control tube. Tubes were incubated 20 min. at 37°C with gentle agitation.
- 25 5. The stimulated HUVEC assay plate was removed from the incubator and the wells were washed one time with cDMEM and the medium was removed from the wells with a pasteur pipette, a few wells at a time.
- 30 6. The cell suspensions and the assay plate were placed in an ice bath to chill for 20 min.
- 35 7. 0.4 ml of cell suspension was added to each well of the previously described assay plate. Control cells were plated on unstimulated and stimulated HUVEC. Antibody treated cells were added to stimulated wells only. Each assay was done in triplicate.

WO 91/19501

PCT/US91/03592

53

8. 0.4 ml aliquots of each cell suspension were added to glass tubes to be used to determine the input CPMS.

9. The assay plate was incubated for 30 min. at 4°C.

The remaining steps of the assay were performed as described in steps 11-15 of Section A, above, except that in step 12 the plates were allowed to stand for 15 min.

10 The results shown, in Figs. 3A and 3B, indicate that the monoclonal antibodies SNH-3, FH6, SNH-4 and CSLEX-1 (all specific for SLX) significantly blocked the binding of LEC11 cells to IL-1 β stimulated HUVEC via the ELAM-1 receptor. LEC12 cells, which do not express the SLX epitope, did not bind the activated endothelium. The monoclonal antibodies specific for Le^x (FH2 and SH1) caused minor inhibition of LEC11 binding.

15 Further confirmation that SLX is a primary ligand for ELAM-1 receptor was provided by removing sialic acid from LEC 11 and HL-60 cells. In these experiments the treatment of LEC 11 and HL-60 cells prior to adhesion assays with Clostridium perfringens neuraminidase (sialidase), 1.6 U/ml (Type X, Sigma Chem. Co.) for 90 min. at 37°C during ⁵¹Cr-labelling. The results, shown in Fig. 4, confirm that sialidase substantially reduced the adhesion of LEC 11 and HL-60 cells by 70-85% to activated endothelial cells.

EXAMPLE IV

Liposomes of Glycosphingolipids Block Binding of SLX Cells to Activated Endothelial Cells

30 This Example describes the preparation of liposomes which contain various biosynthetically produced glycosphingolipids on which the terminal carbohydrate units are either SLX, Le^x, or similar but not identical compounds. The ability of the liposomes which contain SLX or SLX mimetics to block the binding of SLX-expressing HL-60 cells and LEC11 cells to endothelial cells which have been stimulated to express ELAM-1 by treatment with IL-1 β is shown.

WO 91/19501

PCT/US91/03592

54

Materials: The glycosphingolipids used in this experiment are shown in Table I; they were obtained from the Biomembrane Institute, Seattle, WA, and were either purified or biosynthetically produced and characterized by NMR and mass spectrometry, as generally described in Hakomori, S. I., et al., J. Biol. Chem., 259:4672 (1984), and Fukushi Y., et al., J. Biol. Chem. 259:10511 (1984), incorporated by referenced herein. S-diLe^x (SLX) was synthesized enzymatically by adding fucosyl residues using a colo 205 cell line as enzyme source and SH as substrate. Nonsialylated diLe^x was similarly synthesized using nLc6 as substrate and the cell line NCI H-69. See Holmes et al., J. Biol. Chem. 260:7619 (1985), incorporated by reference herein. SPG and SH were purified from bovine red blood cells, and nLc6 was produced by chemical removal of the terminal sialosyl residue from SH.

WO 91/19501

PCT/US91/03592

Table 1. Glycolipids tested for liposome inhibition of ELAM-1 mediated cell adhesion.

Generic	IUPAC	Structure
nLc ₆	nLc ₆	Galβ1→4GlcNAcβ1→3Galβ1→4GlcNAcβ1→3Galβ1→4Glcβ1→1Cer
diLex	III ₃ V ₃ Fuc ₂ nLc ₆	Galβ1→4GlcNAcβ1→3Galβ1→4GlcNAcβ1→3Galβ1→4Glcβ1→1Cer <div style="display: flex; justify-content: space-around; align-items: center;"> <div style="text-align: center;"> ³ ↑ Fuca1 </div> <div style="text-align: center;"> ³ ↑ Fuca1 </div> </div>
SPG	IV ₃ NeuAcnLc ₄	NeuAcα2→3Galβ1→4GlcNAcβ1→3Galβ1→4Glcβ1→1Cer 5 5
SH	VI ₃ NeuAcnLc ₆	NeuAcα2→3Galβ1→4GlcNAcβ1→3Galβ1→4GlcNAcβ1→3Galβ1→4Glcβ1→1Cer
S-diLex	III ₃ V ₃ Fuc ₂ VI ₃ NeuAcnLc ₆	NeuAcα2→3Galβ1→4GlcNAcβ1→3Galβ1→4GlcNAcβ1→3Galβ1→4Glcβ1→1Cer <div style="display: flex; justify-content: space-around; align-items: center;"> <div style="text-align: center;"> ³ ↑ Fuca1 </div> <div style="text-align: center;"> ³ ↑ Fuca1 </div> </div>

WO 91/19501

PCT/US91/03592

56

Liposomes containing the glycosphingolipids were formed as follows: 100 μg of glycolipid was added to 300 μg phosphatidylcholine (Sigma, egg yolk) and 500 μg cholesterol (Sigma) in chloroform-methanol (2:1) and the whole solution
5 evaporated to dryness by N_2 in 15 ml screwcap tubes.

Passage 3 HUVEC, which had been grown on to confluence on a gelatin coated 48 well assay plate (Costar) were used as the source of endothelial cells. The plates were prepared as previously described. Two sets of triplicate wells
10 were left unstimulated as controls. 14 triplicates were stimulated with IL- 1β at 30 $\mu\text{g}/\text{ml}$ in a 0.5 ml volume of EGM-UV. Cells were stimulated for exactly 4 hrs. HL-60 cells and LEC11 cells were cultured as described above.

15 Procedure:

1. One 48 well Costar cluster dish containing HUVEC grown to confluence on gelatin was removed from the incubator and the medium in each well was removed with a pasteur pipette and replaced either with 0.5 ml fresh EGM-UV medium or with the
20 same medium containing 30 $\mu\text{g}/\text{ml}$ IL- 1β , and the plate then returned to the incubator for 4 hrs.

2. HL-60 cells and LEC11 cells were harvested and washed in CRPMI. A viable cell count was made using trypan
25 blue. 6×10^6 cells of each cell type were radiolabeled as follows: 3×10^6 cells of each type were placed in each of 2, 10 ml test tubes and 300 μl of ^{51}Cr (450 μCi) (New England Nuclear) was added to each tube. The tubes were allowed to incubate 1 hr. at 37°C with gentle agitation.

30

3. Radiolabeled HL-60 and LEC11 cells were washed 3X in CRPMI and pooled into one tube. They were then centrifuged and resuspended to 2×10^6 cells per ml in the same
medium.

35

4. The stimulated HUVEC assay plate was removed from the incubator and the wells were washed two times with RPMI 1640 containing 5 mg/ml bovine serum albumin (BSA).

WO 91/19501

PCT/US91/03592

57

5. Liposomes were prepared as follows: The evaporated pellets were dissolved in 100 μ l of absolute ethanol and sonicated for 2 min. Two ml of PBS was added slowly to the tubes over two minutes while continuing to sonicate. This stock was diluted 1:10 in RPMI 1640 medium just prior to use and 50 μ l of a stock solution of BSA at 100 mg/ml was added to each 1 ml of diluted liposomes to make a final concentration of 5 mg/ml BSA.

10

6. The medium was removed from the wells of the assay plate with a pasteur pipette, a few wells at a time, and 0.3 ml of liposome suspension was added to each of 6 IL-1 β stimulated assay wells. Control wells received the liposome buffer containing ethanol, RPMI 1640 and BSA at the same concentrations as in the liposome containing wells. Control buffer was plated on unstimulated and stimulated HUVEC. Liposome containing samples were added to stimulated wells only.

20

7. The plates were incubated for 40 min. at 37°C and then 50 μ l of 51 Cr labeled HL-60 or LEC11 cells were added to the assay wells. Each cell line was assayed in triplicate on each liposome preparation. The final concentration of cells was 10⁵/350 μ l/well. Three aliquots of 50 μ l of each cell suspension were added to glass tubes to be used to determine the input CPMs, and the assay plate incubated at 37°C for 30 min.

30

8. Unbound cells were removed from the wells of the assay plates by systematic resuspension using a pasteur pipette followed by addition and removal of 0.7 ml of medium. All of the medium was removed from the wells and a solution of 0.125 M Tris, 2% SDS and 10% glycerin was added (0.3 ml). The plates were allowed to stand for 15 min. and then 0.5 ml of dH₂O was added to each well.

35

WO 91/19501

PCT/US91/03592

58

9. The fluid in each well was resuspended and transferred to a glass test tube. The pipette tip was ejected into the tube. The tubes, including those containing the input CPM samples, were counted in a gamma counter. CPMs bound in
5 each well were divided by the input CPMs for each sample to determine the % bound. The means and standard error of triplicate assay points were plotted.

As shown in Fig. 5, liposomes containing selected
10 glycolipids having terminal sequences which contained SLX (S-diLe^x, Table 1) dramatically inhibited adhesion of HL-60 cells to activated endothelial cells at 4°C. Liposomes containing glycolipids with Le^x (di-Le^x) or other related carbohydrate structures (Table 1) exhibited minimal inhibition that was not
15 dependent on the structure of the carbohydrate group. Similar results were obtained with LEC 11 cell adhesion. When the experiments were performed at 37°C, HL-60 cell adhesion was reduced by liposomes containing glycolipids with the SLX structure (S-diLe^x, 70%), and also to a lesser extent by
20 liposomes containing Le^x (di-Le^x, 40%) suggesting that Le^x may also interact with ELAM-1, but with a lower affinity. These experiments show that biosynthetically produced SLX or similar SLX mimetic compounds when formulated into liposome compositions can serve as therapeutic compounds for, e.g., the
25 reduction of leukocyte infiltration into inflammatory sites.

Jurkat cells bind to IL-1 activated endothelial cells predominantly through the V-CAM (endothelial cell) - VLA-4 (Jurkat cell) adhesion pair (Wayner et al., J. Cell Biol. 109:1321), in contrast to the adhesion of HL-60 and LEC 11
30 cells to activated endothelial cells through the ELAM-1 receptor. Jurkat cell adhesion was not inhibited by liposomes which contained SLX, but was completely inhibited by monoclonal antibody to the α subunit of the integrin molecule VLA-4. This result demonstrates that SLX liposome inhibition of HL-60 and
35 LEC 11 cells is not a steric effect attributable to binding of liposomes to endothelial cells, but supports the conclusion that SLX liposomes inhibit the adhesion through a direct competition with the ligand binding site of ELAM-1.

WO 91/19501

PCT/US91/03592

59

EXAMPLE VAntibodies to SLX Inhibit GMP-140 Mediated5 Binding on Activated Human Platelets

In this Example the ability of monoclonal antibodies specific for SLX and for the unsialylated Le^x to block the GMP-140 mediated adhesion of HL-60 cells to activated human platelets was determined.

10 Materials: HL-60 cells are described above and were used as the source of ligand bearing cells. Jurkat cells were used as the non-ligand bearing control. Monoclonal antibodies SH-1, FH-2, SNH-4, and CSLEX-1 are also described above.

15 Procedure:

1. Blood was drawn from a normal human donor into a syringe containing ACD anticoagulant (dextrose, 2.0 g; sodium citrate 2.49 g; and citric acid 1.25 g; to 100 ml with dH₂O) at a ratio of 6 parts blood to 1 part anticoagulant.

20 Platelets were isolated by differential centrifugation as follows: Blood was centrifuged at 800 rpm (approx. 90 x g) for 15 min. at room temp. The supernatant was collected and centrifuged at 1200 rpm (approximately 400 x g) for 6 min. The supernatant was removed and centrifuged at 2000
25 rpm (1200 x g) for 10 min. to pellet the platelets. The platelet button was washed 2 times with Tyrode-HEPES buffer, -pH 6.5 (NaCl 8.0 g; KCl 0.2 g; NaH₂PO₄·H₂O 0.057 g; MgCl₂·6H₂O 0.184 g; NaHCO₃ 0.1 g; Dextrose, 1.0 g; and HEPES, 2.383 g; bring to 1 L with DI water, adjust to pH 6.5 with 1N NaOH) followed by
30 one wash in PBS. Platelets were suspended to a concentration of 10⁸/ml in PBS.

2. Approximately 20 min. before the platelets were finally resuspended, 48 well plates were coated with 0.1%
35 gelatin and incubated to 15 min. at 37°C. Excess gelatin was removed by pipette immediately fore the addition of the platelet suspension. Platelets were activated by the addition of 0.25 units of thrombin/ml (Sigma T-6759) of platelet

WO 91/19501

PCT/US91/03592

60

suspension. Platelets were allowed to stand at room temperature for 20 min.

3. To prepare bound, activated platelets, 300 μ l of the platelet suspension was added to each well of the gel coated plate. The plate was incubated at 37°C to 15 min., then spun at 800 rpm (90 xg) for 2 min. The unbound platelets were removed by washing the plate 3 times with PBS.

4. Since platelets possess highly reactive Fc receptors, to prevent uptake of any aggregated IgG from the antibody preparation, the platelet Fc receptors were blocked as follows: Purified mouse IgG W6/32 (IgG_{2a}) at 27 mg/ml was aggregated by heating at 63°C for 5 min. 300 μ l of the heated preparation at 20 μ g/ml in PBS was added to each well of the platelet-coated plate. The plate was incubated at 37°C for 15 min. then washed with PBS.

5. HL-60 and Jurkat cells were harvested and washed in CRPMI. A viable cell count was made using trypan blue, 3 x 10⁶ cells of each type were placed in each of 2, 10 ml test tubes and 300 μ l of ⁵¹Cr (450 μ Ci) (New England Nuclear) was added to each tube. The tubes were incubated for 1 hr. at 37°C with gentle agitation.

6. Radiolabeled cells were washed 3X in CRPMI and pooled into one tube. They were then centrifuged and resuspended to 4 x 10⁶ cells per ml in the same medium.

7. 1.6 ml of each monoclonal antibody culture supernatant, and 1.6 ml of purified CSLEX-1 (15 μ g) were added to separate test tubes; control tubes received 1.6 ml of medium.

8. 100 μ l of the labeled HL-60 or Jurkat cell suspension (containing 4 x 10⁵ cells) was added to each of the tubes which contained monoclonal antibody. They were incubated for 20 min. at 37°C with gentle agitation. Following this

WO 91/19501

PCT/US91/03592

61

incubation period, 0.3 ml of each cell suspension (containing 7.5×10^4 cells) was added to each well of the previously described assay plate containing bound activated platelets. Each assay was done in triplicate.

5

9. The assay plate was centrifuged at 90 xg for 2 min. and then incubated for 5 min. at room temp. Unbound cells were removed from the wells of the assay plate by inverting the plate into a radioactive waste receptacle and blotting the plate on towels. The wells were washed X3 by carefully adding 300 μ l PBS to each well and inverting and blotting the plate. All of the medium was removed from the wells and 0.3 ml of a solution of 0.125 M Tris, 2% SDS and 10% glycerin was added. The plates were allowed to stand for 15 min. and then 0.6 ml of dH_2O was added to each well.

10. The fluid in each well was resuspended with a pipette and transferred to a glass test tube. The tip was ejected into the tube. The tubes, including those containing the input samples, were counted in a gamma counter. CPMS bound in each well were divided by the input CPMS for each sample to determine the % bound. Input CPMS were determined by counting a 0.3 ml aliquot of each cell suspension described in step 8.

The results, shown in Fig. 6, indicate that the monoclonal antibodies SNH-4 and CSLEX-1 specific for SLX blocked the binding of HL-60 cells to GMP-140 on activated platelets. The monoclonal antibodies specific for Le^x (FH2 and SH-1) also blocked this binding but to a lesser extent. This Example suggests that both SLX and Le^x may be ligands for GMP-140, but that the SLX structure may be of a higher affinity for GMP-140 than the Le^x structure.

EXAMPLE VI

Liposomes of Glycosphingolipids Block Binding of SLX Cells to Activated Platelets

35

This Example demonstrates the ability of the liposomes which contain SLX or SLX mimetics to block the binding of SLX-expressing HL-60 cells and PMNs to platelets

WO 91/19501

PCT/US91/03592

62

which have been stimulated to express GMP-140 by treatment with Thrombin. The assays generally followed the protocol described in Larsen et al., Cell 63: 467-474 (1990), which is incorporated herein by reference.

5 **Materials:**

Glycosphingolipids were prepared as described in Example IV. The platelets were prepared as described in Example V, except that blocking of Fc receptors was not performed. HL60 cells were prepared as described above.

10 PMNs were prepared from 50 ml of whole blood drawn from volunteer donors into heparinized vacutainer tubes, which were inverted to mix the blood. All steps were performed at 22-24 degrees C. Each 25 ml of blood was layered over 15 ml of Mono-Poly Resolving Medium (Flow Labs). The tubes were
15 centrifuged at 800xg for 25 min followed by 1300xg for a further 25 min. The PMN layer was removed and placed in a clean 50cc centrifuge tube. Thirty ml of Hanks Balanced Salt Solution (Gibco) containing 20mM HEPES (Gibco) and 0.2% glucose (Fisher) was added to each tube, which were then
20 centrifuged at 1900xg for 3 min. The PMNs were washed 3X in the same buffer by centrifugation at 1900xg for 3 min. PMNs were counted using a hemacytometer and resuspended to 2×10^6 /ml and held at room temperature until use.

25 **Procedure**

1. 20 ul of preparation of activated platelets were placed in each of 28 1.5 ml eppendorf tubes (14 duplicate samples).
2. 20 ul of the diluted liposomes at 10 ug, 5 ug or
30 2 ug, or of the control buffers, were added to the appropriate tube of each duplicate.
3. The platelets were incubated with the liposome preparations for 20 min. at room temp.
4. Neutrophils or HL-60 cells at 2×10^6 cells/ml
35 were each added to one set of liposome treated platelets. 20 ul of cell suspension were added to each tube.
5. The tubes were mixed and allowed to stand at room temperature for 20 min. Then they were applied to a

WO 91/19501

PCT/US91/03592

63

hemacytometer and the cells were scored as positive (2 or more platelets attached/cell) or negative (less than 2 platelets attached/cell).

As shown in Fig. 7, liposomes containing selected glycolipids having terminal sequences which contained SLX (S-diLe^x, Table 1) dramatically inhibited adhesion of HL-60 cells to activated platelets. Liposomes containing glycolipids with Le^x (di-Le^x) or other related carbohydrate structures (Table 1) exhibited minimal inhibition that was not dependent on the structure of the carbohydrate group. Similar results were obtained with PMN cell adhesion (Fig. 8). These experiments show that biosynthetically produced SLX or similar SLX mimetic compounds when formulated into liposomes compositions can serve as therapeutic compounds for, e.g., the reduction of leukocyte binding to platelets in inflammatory sites.

EXAMPLE VII

Hexasaccharide SLX blocks binding of Neutrophils to platelets

In this example the ability of a minimal tetra-saccharide SLX to inhibit GMP-140 adhesion was compared to that of a hexasaccharide SLX. Briefly, platelets and neutrophils were isolated by the methods described above. Platelets were activated with thrombin and then incubated with dilutions of various oligosaccharides. Neutrophils were added and the effect of the saccharides on the adhesion of neutrophils to activated platelets was determined. The oligosaccharides used were as follows: SLX(hexa), NeuAc α 2,3Gal β 1,4 (Fuc α 1,3) GlcNAc β 1,3 Gal β 1,4Glc-O-CH₂CH₂SiMe₃ (the generous gift of Professor Hasegawa, Gifu University, Japan) and SLX(tetra), NeuAc α 2,3Gal β 1,4 (Fuc α 1,3)GlcNAc.

Procedure

1. Platelets were isolated as described above and were activated (2×10^8 /ml) by incubation for 20 min at room temperature with thrombin at a final concentration of 0.25U/ml.

WO 91/19501

PCT/US91/03592

64

2. Neutrophils were isolated by layering heparinized blood over Mono-Poly Resolving Medium (Ficoll-Hypaque-Flow Laboratories), followed by centrifugation for 25 min at 2000rpm and then, a further 25 min at 2500rpm as described above.
3. For the assay, 20 μ l of the platelet suspension (2×10^8 /ml) was placed in an Eppendorf centrifuge tube. An equal volume of the oligosaccharide preparations at concentrations from 500 μ g/ml to 2.0 μ g/ml, or of glycolipid-liposome preparations (prepared as described, above), at concentrations from 2 μ g/ml to 0.25 μ g/ml, was added and the tubes were allowed to stand at room temperature for 20 min. Twenty μ l of the neutrophil preparation (2×10^6 /ml) was then added and the tubes were allowed to stand for a further 20 min at room temperature.
4. Adhesion of activated platelets to the neutrophils was assessed microscopically. One hundred neutrophils were evaluated. They were scored as positive if 2 or more platelets were attached and negative if less than 2 platelets were bound. The percent of cells with 2 or more bound platelets was calculated.
- The results of two identical experiments are shown in Table 2.

WO 91/19501

PCT/US91/03592

65

TABLE 2

5	OLIGOSACCHARIDE	AMOUNT REQUIRED FOR 50% INHIBITION (μ M)	
		EXPERIMENT 1	EXPERIMENT 2
10	SLX (hexa)	4.0	2.2
	SLX (tetra)	69.0	54.0
	Le ^x	78.0	43.0

15

As indicated in Table 2 above, approximately 20 times more of the SLX-tetra saccharide is required for 50% inhibition of GMP-140 mediated binding of neutrophils to thrombin activated platelets than of the SLX-hexa saccharide. The amount of the tetra-saccharide required is approximately that needed for a similar degree of inhibition when the non-sialylated Le^x was used. These results suggest that the 5-6 sugar SLX moiety, especially including the GlcNAc β 1,3Gal structure constitutes a portion of the ligand for GMP-140 necessary for binding.

20

WO 91/19501

PCT/US91/03592

66

EXAMPLE VIII

Blocking adhesion using variant SLX structures

This example describes experiments testing various glycolipid structures on liposomes. In particular, SY2, a sialylated polysaccharide in which the fucose instead of being attached to the ultimate GlcNAc as in SLX, is attached to the penultimate GLcNAc was tested. Platelets and neutrophils were isolated by the methods described above. Platelets were activated with thrombin and then incubated with dilutions of various glycolipids embedded in liposomes prepared as described above. Neutrophils were added and the effect of the glycolipids on the adhesion of neutrophils to activated platelets was determined.

Structures of the various glycolipids examined are as follows: SDiY2, NeuGc α 2,3Gal β 1,4(Fuca1,3)GlcNAc β 1,3Gal β 1,4(Fuca1,3)GlcNAc β 1,3Gal β 1,4Glc β 1,1Cer; SLX, NeuGc α 2,3Gal β 1,4(Fuca1,3)GlcNAc β 1,3Gal β 1,4Glc β 1,1Cer; SY2, NeuGc α 2,3Gal β 1,4GlcNAc β 1,3Gal β 1,4(Fuca1,3)GlcNAc β 1,3Gal β 1,4Glc β 1,1Cer; SH, NeuGc α 2,3Gal β 1,4GlcNAc β 1,3Gal β 1,4GlcNAc β 1,3Gal β 1,4Glc β 1,1Cer; SPG, NeuGc α 2,3Gal β 1,4GlcNAc β 1,3Gal β 1,4Glc β 1,1Cer.

The results of two identical experiments are shown in Table 3.

25

WO 91/19501

PCT/US91/03592

67

Table 3

	GLYCOLIPID	AMOUNT REQUIRED FOR 50% INHIBITION (μ M)
5		
	SY2 (Exp 1)	0.325
10	SY2 (Exp 2)	0.345
	SLX (hexa)	0.30
	SdiY2	0.36
15	SPG	No Inh.
	SH	No Inh.

20

These results show that SY2 inhibited GMP-140 mediated adhesion of neutrophils to thrombin activated platelets equally as well as did SLX and SDiY2.

25

WO 91/19501

PCT/US91/03592

68

EXAMPLE IX

Blocking adhesion using further variants of SLX

The example demonstrates that the affinity of sialylated Le^x(SLX) for GMP-140 is the same whether the terminal sialic acid is in the form N-Acetyl neuraminate (NeuAc) or N-Glycol neuraminate (NeuGc). All materials were prepared as described above. Platelets and neutrophils were isolated by the methods described. Platelets were activated with thrombin and then incubated with dilutions of various glycolipids contained in liposomes. Neutrophils were added and the effect of the glycolipids on the adhesion of neutrophils to activated platelets was determined.

The results of an experiment in which synthetic SLX(NeuAc) and a preparation of SLX prepared by enzymatic fucosylation of of sialylparagloboside purified from bovine erythrocytes SLX(NeuGc), were directly compared are shown in Table 4.

20

Table 4

GLYCOLIPID	SOURCE	AMOUNT REQUIRED FOR 50% INHIBITION (μ M)
SLX (NeuGc)	(Bovine Erythrocytes)	0.74
SLX (NeuAc)	(Synthetic)	0.67

These results show that SLX-hexasaccharide inhibited GMP-140 mediated adhesion of neutrophils to thrombin activated platelets equally well whether the sialic acid was NeuAc or NeuGc. This result indicates that either the N-acetyl or N-glycolyl derivative of sialic acid would also allow recognition of SLX by ELAM-1.

WO 91/19501

PCT/US91/03592

69

Various glycolipids were also tested in the same assay. The results are presented in Figure 9. Structures of the glycolipids tested are as follows: SLX(hexa), NeuGc α 2,3Gal β 1,4(Fuca1,3)GlcNac β 1,3Gal β 1,4Glc β 1,1Ceramide; α 2,3 SLX cer, NeuAc α 2,3Gal β 1,4(Fuca1,3)GlcNac β 1,3Gal β 1,4Glc β 1,1Ceramide; α 2,6 SLX cer, NeuAc α 2,6Gal β 1,4(fuca1,3)GlcNac β 1,3Gal β 1,4Glc β 1,1Ceramide; SH, NeuGc α 2,3Gal β 1,4GlcNac β 1,3Gal β 1,4GlcNac β 1,3Gal β 1,4Glc β 1,1Ceramide.

10

EXAMPLE X

Blocking adhesion using synthetic SLX

This example demonstrates that synthetic SLX binds ELAM-1 and inhibits neutrophil adhesion to activated endothelium. This example also shows that the linkage of the sialic acid affects binding to ELAM-1.

Two synthetic compounds were prepared. One comprised sialic acid in an α 2.3 linkage, as in naturally occurring SLX. The second comprised sialic acid in an α 2,6 linkage, to examine the importance of the nature of the linkage to receptor binding.

Liposomes were prepared by adding 12 μ l of absolute ETOH to each tube, warming briefly in a 50°C water bath and sonicating for 2 min. 238 μ l of warm phosphate buffered saline (PBS) was added slowly to each tube while sonicating and sonication was continued for a further 10 min. The final concentration of stock liposomes was 400 μ g glycolipids/ml in 5% ETOH/PBS.

30

Procedure

1. HUVECs, PMNs, and liposomes were prepared as described above.
2. The stimulated HUVEC assay plate was removed from the incubator and the wells were washed two times with RPMI 1640 containing 5 mg/ml bovine serum albumin (BSA).

35

WO 91/19501

PCT/US91/03592

70

3. Liposomes stocks were diluted in the HBSS/BSA buffer to make solutions equal to: 40 $\mu\text{g/ml}$, 30 $\mu\text{g/ml}$, 15 $\mu\text{g/ml}$, 7.5 $\mu\text{g/ml}$, 3.75 $\mu\text{g/ml}$ and 1.87 $\mu\text{g/ml}$. Similar dilutions were prepared from a control stock consisting of PBS-5% ETOH.
4. The medium was removed from the wells of the assay plate with a pasteur pipette, a few wells at a time.
5. 0.05 ml of each liposome suspension was added to duplicate wells on the stimulated assay plate. Control wells received the liposome buffer containing ethanol HBSS and BSA at the same concentrations as in the liposome containing wells. Control buffer was plated on unstimulated and stimulated HUVEC. Liposome containing samples were added to stimulated wells only.
6. The plates were incubated for 40 min at 37°C and then 50 μl of PMNs were added to the assay wells. The final concentration of cells was 5×10^5 well in 100 μl .
7. The assay plate was returned to the incubator (5% CO_2 , 37 °C) for 8 min.
8. Unbound cells were removed from the wells of the assay plates by systematic resuspension using a p200 multichannel pipette followed by addition and removal of 0.2 ml of medium.
9. All of the medium was removed from the wells and 50 μl of solubilization buffer was added. This consisted of citrate buffer (24.3 ml of 0.1 M Citric acid, 10.5 g/500 ml + 25.7 ml of 0.2 M dibasic sodium phosphate, 14.2 g/500 ml and $\text{SQ H}_2\text{O}$ to 100 ml) containing 0.1% NO-40 detergent.
10. The plate was incubated on a rotary shaker for 10 min and then 0.05 ml of OPDA solution [8 mg o-phenylene-diamine, Sigma cat# P-1526, 8 μl of 30% H_2O_2 and 10 ml of citrate

WO 91/19501

PCT/US91/03592

71

buffer (as above)] was added to each well. The reaction was allowed to develop for 15 min and then 25 μ l of 4N H_2SO_4 was added to each well to stop the reaction.

- 5 11. A reagent bulk was prepared by mixing 100 μ l volumes of the solubilization buffer and the OPDA solution with 50 μ l of 4N H_2SO_4 .
- 10 12. 100 μ l of supernatant was removed from each of 2 wells and transferred to a flexible ELISA assay plate (Falcon). The plate scanned spectrophotometrically at 492 nm within 30 min.

15 The results of the two experiments are presented in Table 5, below.

		Table 5		
		(2,6) SLex		(2,3) SLex
		Concentration	Mean	Mean
20	1	20 μ g/ml	0.663	0.156
	2	15 μ g/ml	0.636	0.270
	3	7.5 μ g/ml	0.602	0.359
	4	3.75 μ g/ml	0.655	0.483
	5	1.87 μ g/ml	0.690	0.580
25	6	.47 μ g/ml	0.695	0.642
	7	0 μ g/ml	0.710	0.716
		Control +1L-1B		Control -1L-1B
		Concentration	Mean	Mean
30	1	20 μ g/ml	0.657	0.010
	2	15 μ g/ml	0.740	0.010
	3	7.5 μ g/ml	0.658	0.013
	4	3.75 μ g/ml	0.698	0.009
35	5	1.87 μ g/ml	0.725	0.014
	6	.47 μ g/ml	0.782	0.018
	7	0 μ g/ml	0.708	0.016

WO 91/19501

PCT/US91/03592

72

These results show that liposomes containing synthetic $\alpha(2,3)$ SialylLe^x but not $\alpha(2,6)$ SialylLe^x inhibit neutrophil adhesion to activated endothelium in an ELAM-1 dependent binding assay. Thus, the $\alpha 2,3$ linkage of the sialic acid appears to be necessary for recognition by ELAM-1. In addition, the results show that a synthetically produced oligosaccharide, $\alpha(2,3)$ SialylLe^x, binds to ELAM-1 and blocks binding of neutrophils to activated endothelium. This compound or derivatives of this compound therefore constitute potential anti-inflammatory drug candidates.

EXAMPLE XI

Treatment of HL60 Cells with Endo- β -Galactosidase

This example describes experiments to determine whether the internal β -galactose-backbone sugar linkage of sialylated Le^x of HL60 cells was susceptible to cleavage by Endo- β -Galactosidase, an enzyme known to cleave an internal β -galactose linkage in polylactosaminyll structures, but not β -gal when GlcNAc is attached to mannose (core-type structures).

Procedure:

Platelets were isolated and activated with thrombin by the methods described above. Cultured HL60 cells were treated with endo- β -galactosidase as described below and the effect of enzyme treatment on the GMP-140 mediated adhesion of HL60 cells to activate platelets was determined.

Enzyme treatment of the HL60 cells was carried out as follows: 12.4×10^6 cells were washed twice with Hanks Balanced Salt Solution containing 20mM HEPES and 0.2% glucose, followed by a single wash step in normal saline. The endo- β -galactosidase (0.1 Unit, ICN Chemicals, Inc., Irvine, CA) was dissolved in 200 μ l normal saline and 200 μ l sodium acetate buffer, pH 6.01. 200 μ l (containing 0.05U of enzyme) was added to 3×10^6 HL60 cells, and 200 μ l of the acetate buffer was added to a similar number of cells to be used as the buffer control. Both tubes were incubated at 37°C for 60 min. with

WO 91/19501

PCT/US91/03592

73

gentle shaking. The tubes were then cooled in ice and the cells were washed three times in HBSS containing HEPES and glucose and were then counted and suspended to $2 \times 10^6/\text{ml}$.

For the assay, $20 \mu\text{l}$ of Tyrode-HEPES buffer, pH 7.2 was placed in an Eppendorf tube. The same volume of activated platelets ($2 \times 10^8/\text{ml}$) and HL60 cells ($2 \times 10^6/\text{ml}$) was added and, after mixing, the tubes were allowed to stand at room temperature for 20 min. Adhesion of platelets to the HL60 cells was assessed microscopically as described earlier for adhesion of activated platelets to neutrophils.

The results of these experiments indicated that treatment of HL60 cells with Endo- β -Galactosidase inhibited their ability to bind to thrombin activated platelets by 87.5%. Thus, the minimal SLX-containing tetrasaccharide ligand for GMP-140 is probably attached to a lactose or polylactosaminyll structure rather than a mannose.

EXAMPLE XII

Fucosylated Polysaccharide blocks binding of Neutrophils to Platelets

In this example the ability of a fucosylated polysaccharide to inhibit GMP-140 mediated adhesion was compared to that of the non-fucosylated polysaccharide, a hexasaccharide SLX and Le^x . Briefly, platelets and neutrophils were isolated by the methods described above. Platelets were activated with thrombin and then incubated with dilutions of various oligosaccharides. Neutrophils were added and the effect of the saccharides on the adhesion of neutrophils to activated platelets was determined. The oligosaccharides used were as follows: Native polysaccharide and its fucosylated derivative (the preparation of both is described, below); SLX hexasaccharide, LNF III (Le^x) and LNF I (the structures are described above).

The conversion of a polysaccharide which contains the linear core structure of SLX into a polyvalent SLX containing polysaccharide was achieved by enzymatic fucosylation. The native polysaccharide type Ia was obtained from Group B Streptococcus as described by Jennings et al., Biochem. 22 1258-1263 (1983) which is incorporated herein by reference.

WO 91/19501

PCT/US91/03592

74

The appropriate bacterial strains are deposited with the American Type Culture Collection and have Deposit Nos. 12400, 31574, 12401, and 31575.

To prepare the fucosylated polysaccharide, the native
5 type Ia polysaccharide 1 mg. was dissolved in a mixture of 6 μ L of 1 M manganese chloride, guanosine 5'-diphosphate β -L-fucose with a radiolabelled tracer (specific activity 1.82×10^6 cpm/ μ mol), 0.9 μ moles in water 90 μ L and water 137 μ L. To this was added 100 μ L solution of 3/4 fucosyl transferase isolated
10 from human milk as previously described by Prieels et al., J.Biol.Chem. 256 10456-10463 (1981) which is incorporated herein by reference.

The reaction mixture of concentrated against a membrane (100K cut off) several times with water and the
15 retentate lyphsized to give a powder. Resuspension and counting of label indicated approximately one half (i.e., about 100) of the available acceptor side chains had been fucosylated.

Procedure:

20 Platelets were isolated as described above and were activated (2×10^8 /ml) by incubation for 20 min at room temperature with thrombin at a final concentration of 0.25U/ml.

Neutrophils were isolated by layering heparinized blood over Mono-Poly Resolving Medium (Ficoll-Hypaque, Flow
25 Laboratories), followed by centrifugation for 25 min at 2000rpm and then, a further 25 min at 2500rpm as described above.

For the assay, 20 μ l of the platelet suspension (2×10^8 /ml) was placed in an Eppendorf centrifuge tube. An equal volume of the oligosaccharide preparations at
30 concentrations from 500 μ g/ml to 2.0 μ g/ml was added and the tubes were allowed to stand at room temperature for 20 min. Twenty μ l of the neutrophil preparation (2×10^6 /ml) was then added and the tubes were allowed to stand for a further 20 min at room temperature.

35 Adhesion of activated platelets to the neutrophils was assessed microscopically. One hundred neutrophils were evaluated. They were scored as positive if 2 or more platelets were attached and negative if less than 2 platelets were bound.

WO 91/19501

PCT/US91/03592

75

The percent of cells with 2 or more bound platelets was calculated.

As shown in Table 6, the fucosylated polysaccharide very efficiently inhibited GMP-140 mediated binding of neutrophils to thrombin activated platelets- 50% inhibition was achieved with less than 1 μ g/ml. This compared to 20 μ g/ml which was required of the native polysaccharide and 8 μ g/ml of the SLX hexasaccharide for a similar degree of inhibition.

10

TABLE 6

OLIGOSACCHARIDE	AMOUNT REQUIRED FOR 50% INHIBITION (μ g/ml)
Native Polysaccharide	20
Fucosylated Polysaccharide	<1
SLX Hexasaccharide	8
LNF III (Le ^x)	35
LNF I	No Inhibition

30

Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be apparent that certain changes and modifications may be practiced within the scope of the appended claims.

WO 91/19501

PCT/US91/03592

76

WHAT IS CLAIMED IS:

1. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound having a selectin-binding oligosaccharide moiety.
2. A composition of claim 1, wherein the oligosaccharide moiety contains fucose and sialic acid.
3. A composition of claim 1, wherein the oligosaccharide moiety is R_1 -Gal β 1,4(Fuc α 1,3)GlcNAc β 1- R_2 , wherein
 - R_1 is selected from the group consisting of NeuAca2,3, NeuGca2,3, NeuAca2,3Gal β 1,4GlcNAc β 1,3, and NeuGca2,3Gal β 1,4GlcNAc β 1,3; and
 - R_2 is selected from the group consisting of 1,3 β Gal, 1,2 α Man, and 1,6 α GalNAc.
4. A composition of claim 1, wherein the oligosaccharide moiety is on a polysaccharide.
5. A composition of claim 4 wherein the polysaccharide is a fucosylated polysaccharide type Ia of Group B streptococcus.
6. A composition of claim 5 wherein the polysaccharide has molecular weight between about 5,000 and 300,000 daltons.
7. A composition of claim 5 wherein the polysaccharide comprises between about 5 and about 200 fucosylated side chains.
8. A composition of claim 7 wherein the polysaccharide comprises between about 50 and about 150 fucosylated side chains.

WO 91/19501

PCT/US91/03592

77

9. A composition of claim 1 wherein the compound is a glycoprotein or a glycolipid.

10. A composition of claim 1, wherein selectin-binding moiety binds a selectin receptor expressed on a vascular endothelial cell or a platelet.

11. A composition of claim 1, wherein the cell surface receptor is ELAM-1 or GMP-140.

12. A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and a liposome having a compound which comprises a selectin-binding oligosaccharide moiety.

13. A composition of claim 12, wherein the liposome encapsulates an anti-inflammatory chemotherapeutic agent.

14. A composition of claim 12, wherein the anti-inflammatory agent is cyclosporin A.

15. A composition of claim 12, wherein the oligosaccharide moiety comprises a fucose and a sialic acid residue.

16. A composition of claim 12, wherein the oligosaccharide moiety is R_1 -Gal β 1,4(Fuc α 1,3)GlcNAc β 1- R_2 , wherein

R_1 is selected from the group consisting of NeuA α 2,3, NeuG α 2,3, NeuA α 2,3Gal β 1,4GlcNAc β 1,3, and NeuG α 2,3Gal β 1,4GlcNAc β 1,3; and

R_2 is selected from the group consisting of 1,3 β Gal, 1,2 α Man, and 1,6 α GalNAc.

17. A composition of claim 12 wherein the compound is a glycoprotein.

WO 91/19501

PCT/US91/03592

78

18. A composition of claim 12 wherein the glycoprotein has a molecular weight between 40,000 and about 250,000 daltons.

5 19. A composition of claim 1, wherein the compound is a glycolipid.

20. A composition of claim 14, wherein the glycolipid has a molecular weight between about 600 and about
10 4,000 daltons.

21. A composition of claim 12, wherein the compound is an oligosaccharide.

15 22. A composition of claim 12, wherein the selectin-binding moiety binds a selectin receptor expressed on a vascular endothelial cell or a platelet.

23. A pharmaceutical composition comprising a
20 pharmaceutically acceptable carrier and a compound having an oligosaccharide moiety capable of selectively binding a selectin, the compound comprising:





wherein

25 L_1 is the oligosaccharide moiety and is selected from the group consisting of SLX and SY2;

X_1 is selected from the group consisting of H, OH, NH_2 , NHR_1 , OR_1 , $OAryl$, $OAlkylAryl$, $OCeramide$, R_1 , $Aryl$, and $AlkylAryl$, wherein R_1 is a C_1 - C_{20} alkyl.

30

24. A compound of claim 23, wherein L is linked to




WO 91/19501

PCT/US91/03592


79

wherein, n and m are the same or different and are integers from 2 to 12; Y is O or S; and W is O, S, or NH; or to



wherein, n and m are integers from 2 to about 12;

10 Y is O or S; and
 W is O, S, or NH, or to



wherein, Z is a 5- to 14-membered ring and the substituents on the ring are in a cis- or trans-relationship, and the substituents are in a 1,2 to 1,(p/2)+1 arrangement, where p is
 20 the size of the ring.

25 25. A composition comprising a heterocyclic compound having two nitrogen atoms and two oligosaccharide moieties of claim 23, each moiety being linked to a nitrogen atom.

26. A composition of claim 25, wherein the heterocyclic compound is a six or seven membered ring, selected from the group of piperazine or homopiperazine.

30 27. A composition comprising an amino acid linked to the oligosaccharide moiety of claim 23.

28. A composition of claim 27, wherein the amino acid is lysine, homolysine, ornithine, diaminobutyric acid,
 35 asparagine or diaminopropionic acid.

29. A composition of claim 28, wherein the amino acid is incorporated in an oligopeptide.

WO 91/19501


PCT/US91/03592

80

30. A composition of claim 29, wherein the oligopeptide comprises lysine, homolysine, ornithine, diaminobutyric acid, asparagine or diaminopropionic acid.

5 31. A composition of claim 30, wherein the oligopeptide further comprises an alanine, tyrosine or radioiodinated tyrosine.

10 32. A composition of claim 31, wherein the oligopeptide comprises, in a direction from the N-terminus to the C-terminus,



wherein R_1 and R_2 are any amino acid residue.

33. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an immunoglobulin
25 capable of selectively binding an oligosaccharide ligand recognized by a selectin cell surface receptor.

34. A composition of claim 33 wherein the ligand comprises the sequence NeuAc α 2,3Gal β 1,4(α 1,3Fuc)GlcNAc β 1.
30

35. A composition of claim 33, wherein the oligosaccharide ligand is expressed by a leukocyte.

36. A composition of claim 33, wherein the selectin
35 is expressed by a vascular endothelial cell or a platelet.

37. A composition of claim 33, wherein the selectin is ELAM-1.

40 38. A composition of claim 33, wherein the immunoglobulin is CSLEX-1, FH6, SNH₃, SNH₄ or VIM-2.

WO 91/19501

PCT/US91/03592

81

39. A composition of claim 33, wherein the composition is in unit dosage form.

5 40. A pharmaceutical composition for inhibiting selectin-mediated intercellular adhesion which comprises a compound capable of selectively binding a selectin receptor.

10 41. A composition of claim 40, wherein the compound comprises an oligosaccharide moiety having a fucose and a sialic acid residue.

42. A composition of claim 41, wherein the oligosaccharide moiety is SLX or SY2.

15 43. A composition of claim 40 wherein the compound is an immunoglobulin.

20 44. A composition of claim 40, wherein the cell surface receptor is expressed on vascular endothelial cells or platelets.

45. A composition of claim 40, wherein the cell surface receptor is ELAM-1 or GMP-140.

25 46. A composition of claim 40 wherein the selectin-mediated intercellular adhesion is associated with an inflammatory disease response.

30 47. A composition of claim 46, wherein the inflammatory disease process is reperfusion injury, asthma, psoriasis, septic shock or nephritis.

35 48. A method for inhibiting selectin-mediated intercellular adhesion in a patient, the method comprising administering a therapeutically effective dose of the pharmaceutical composition of claims 1, 12, 23, 33.

WO 91/19501

PCT/US91/03592

82

49. A method of claim 48, wherein the intercellular adhesion is associated with an inflammatory condition.

50. A method of claim 49, wherein the inflammatory
5 condition is reperfusion injury, asthma, psoriasis, septic shock, or nephritis.

51. A method of inhibiting intercellular adhesion mediated by a selectin cell surface receptor in a patient, the
10 method comprising administering to the patient a therapeutically effective dose of a compound having at least one oligosaccharide moiety capable of selectively binding the cell surface receptor.

52. A method of claim 51, wherein the
15 oligosaccharide moiety comprises a fucose and a sialic acid residue.

53. A method of claim 51, wherein the
20 oligosaccharide moiety is $R_1\text{-Gal}\beta 1,4(\text{Fuc}\alpha 1,3)\text{GlcNAc}\beta 1\text{-}R_2$, wherein

R_1 is selected from the group consisting of NeuAc α 2,3, NeuGc α 2,3, NeuAc α 2,3Gal β 1,4GlcNAc β 1,3, and NeuGc α 2,3Gal β 1,4GlcNAc β 1,3; and

25 R_2 is selected from the group consisting of 1,3 β Gal, 1,2 α Man, and 1,6 α GalNAc.

54. A method of claim 51, wherein the cell surface
30 receptor is ELAM-1 or GMP-140.

55. A method of claim 51 wherein the oligosaccharide moiety is on a liposome.

56. A method of claim 51 wherein the oligosaccharide
35 moiety is on a polysaccharide.

WO 91/19501

PCT/US91/03592

83

57. A method of claim 51 wherein the polysaccharide is a fucosylated polysaccharide type Ia of Group B streptococcus.

5 58. A method of claim 51, wherein the selectin mediates adhesion of a leukocyte, monocyte or neutrophil to the endothelial cell.

59. A method of claim 51, wherein the intercellular
10 adhesion is associated with an inflammatory condition.

60. A method of claim 59, wherein the inflammatory condition is reperfusion injury, asthma, psoriasis, septic shock, nephritis, or traumatic shock.

15 61. A method of claim 51, wherein the intercellular adhesion is associated with metastasis.

62. A method of treating an inflammatory disease
20 process mediated by a selectin cell surface receptor in a patient, the method comprising administering to the patient a therapeutically effective dose of a biomolecule having an oligosaccharide moiety capable of selectively binding the cell surface receptor.

25 63. A method of claim 62, wherein the oligosaccharide moiety contains sialic acid and fucose.

64. A method of claim 62, wherein the biomolecule
30 has a chemical formula selected from the group consisting of
 $\text{NeuAc}\alpha 2,3\text{Gal}\beta 1,4(\text{Fuc}\alpha 1,3)\text{GlcNAc}\beta 1\text{-R}_1$,
 $\text{NeuGc}\alpha 2,3\text{Gal}\beta 1,4(\text{Fuc}\alpha 1,3)\text{GlcNAc}\beta 1\text{-R}_1$, and
 $\text{NeuGc}\alpha 2,3\text{Gal}\beta 1,4\text{GlcNAc}\beta 1,3\text{Gal}\beta 1,4(\text{Fuc}\alpha 1,3)\text{GlcNAc}\beta 1\text{-R}_1$;
wherein R_1 is selected from the group consisting of an amino
35 acid, an oligopeptide, a protein, a glycoprotein, and a polysaccharide.

WO 91/19501

PCT/US91/03592

84

65. A method of claim 62, wherein the cell surface receptor is ELAM-1 or GMP-140.

5 66. A method of assaying a test compound for the ability to inhibit selectin-mediated cellular adhesion, the method comprising the steps of:

contacting the test compound with a selectin receptor and an isolated selectin-binding agent; and

10 detecting the ability of the test compound to inhibit binding between the receptor and the agent.

67. A method of claim 66 wherein the agent comprises an SLX moiety, an SLX mimetic, or an immunoglobulin.

15 68. A method of claim 66 wherein the receptor is on an activated endothelial cell or a platelet.

69. A method of claim 66 wherein the receptor, the agent, or the test compound is labelled.

20 70. A method of claim 66 wherein the receptor or the agent are immobilized on a solid surface.

71. A method of claim 66 wherein the step of
25 detecting the inhibition of binding is carried out by detecting a physiological change in a cell bearing the receptor.

72. A method of claim 66 wherein the test compound is an oligosaccharide or a glycoconjugate.

30 73. A method of claim 66 wherein the test compound comprises fucose and sialic acid.

74. A method of claim 73 wherein the test compound
35 comprises an SLX moiety.

75. A method of claim 66 wherein the test compound is an immunoglobulin.

WO 91/19501

PCT/US91/03592

85

76. A method of assaying for the ability of an oligosaccharide moiety to selectively bind a selectin receptor, the method comprising contacting a test compound having the moiety with the receptor and determining the binding of the compound to the receptor.

77. A method of claim 76 wherein the test compound is labelled.

78. A method of claim 76 wherein the receptor is immobilized on a solid surface.

79. A method of claim 76 wherein the moiety comprises fucose and sialic acid.

80. A method of claim 76 wherein the step of contacting further comprises contacting the test compound with a selectin-binding agent and the step of determining binding is carried out by detecting the inhibition of binding between the receptor and the agent.

81. A method of claim 80 wherein the agent is an immunoglobulin.

82. A method of claim 80 wherein the agent comprises an SLX moiety.

83. A method of assaying a test compound for the ability to selectively bind an SLX moiety, the method comprising contacting the test compound with an isolated SLX moiety and determining the binding of the compound to the isolated SLX moiety.

84. A method of claim 83 wherein the isolated SLX moiety is immobilized on a solid surface.

WO 91/19501

PCT/US91/03592

86

85. A method of claim 83 wherein the test compound is labelled.


86. A method of claim 83 wherein the test compound
5 is an immunoglobulin.

87. A method of claim 83 wherein the step of contacting further comprises contacting the test compound with an SLX-binding agent and the step of determining binding is
10 carried out by detecting the inhibition of binding between the isolated SLX moiety and the SLX-binding agent.

88. A method of claim 87 wherein the SLX-binding agent is an immunoglobulin.
15

89. A method of claim 87 wherein the SLX-binding agent is a selectin receptor.

90. A pharmaceutical composition comprising a
20 suitable carrier and a compound having a selectin-binding oligosaccharide moiety having the formula:



wherein, R_1 is NeuAc α 2,3; NeuGc α 2,3; NeuAc α 2,3Gal β 1,4GlcNac β 1,3;

25 or NeuGc α 2,3Gal β 1,4GlcNac β 1,3;

R_2 is L-Fuc α 1,3; D-Fuc α 1,3; Ara α 1,3; (R,S)-5-alkyl-Ara α 1,3 or (R,S)-5-aryl-Ara α 1,3;

R_3 is 1,3 β Gal; 1,2 α Man; or 1,6 α GalNAc.

30 91. A composition of claim 90, wherein the oligosaccharide moiety is on a glycoprotein or glycolipid.


92. A composition of claim 90, wherein the oligosaccharide moiety binds a selectin receptor expressed on a
35 vascular endothelial cell or a platelet.

93. A composition of claim 90, wherein the cell surface receptor is ELAM-1 or GMP-140.

WO 91/19501

PCT/US91/03592

1/9

*FIG. 1.*SUBSTITUTE SHEET

WO 91/19501

PCT/US91/03592

2/9

mAbs BLOCK BINDING OF HL-60
TO STIMULATED HUVEC AT 37°C.




FIG. 2A. IL-1B
mAb

mAb BLOCK BINDING OF HL-60
TO STIMULATED HUVEC AT 4°C.




FIG. 2B.

IL-1B
mAb

SUBSTITUTE SHEET

WO 91/19501

PCT/US91/03592

3/9


INHIBITION OF LEC11 BINDING TO
ACTIVATED ENDOTHELLUM BY mAb

FIG. 3A.


INHIBITION OF LEC12 BINDING TO
ACTIVATED ENDOTHELLUM BY mAb


FIG. 3B.

SUBSTITUTE SHEET

WO 91/19501

PCT/US91/03592

4/9


**FIG. 4A.**

SUBSTITUTE SHEET

WO 91/19501

PCT/US91/03592

5/9

**FIG. 4B.**

SUBSTITUTE SHEET

WO 91/19501

PCT/US91/03592

6/9




FIG. 5A.

WO 91/19501

PCT/US91/03592

7/9




FIG. 5B.

SUBSTITUTE SHEET

WO 91/19501

PCT/US91/03592




FIG. 6.





FIG. 7.


SUBSTITUTE SHEET

WO 91/19501

PCT/US91/03592

**FIG. 8.**

INHIBITION OF GMP-140 MEDIATED ADHESION
OF NEUTROPHILS BY GLYCOLIPID WITH TERMINAL
SIALIC ACID EITHER NeuAc OR NeuGc

**FIG. 9.****SUBSTITUTE SHEET**

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US91/03592

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) *		
According to International Patent Classification (IPC) or to both National Classification and IPC		
IPC(5): A61K 31/70, 31/715, 39/00		
U.S. CL.: 514/23.54; 536/1.1, 53, 123		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
U.S.	514/23, 54; 536/1.1, 123, 53	
Documentation Searched other than Minimum Documentation to the extent that such Documents are included in the Fields Searched *		
Chemical ABSTRACTS Services: Selection of ELAM and polysaccharide(s) or oligosaccharide(s) or saccharide(s) or carbohydrate(s)		
III. DOCUMENTS CONSIDERED TO BE RELEVANT *		
Category *	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
Y	The Journal of Biological Chemistry, vol. 259, No. 7, issued 10 April 1984, S. Hakomori et al. "Novel Fucolipids Accumulating in Human Adenocarcinoma", pages 4672-4680, see entire document.	1-8,10-11 40-42, 44-54, 56-65, 90 & 92-93
Y	The Journal of Biological Chemistry, vol. 259, no. 7, issued 10 April 1984. Y. Fukushi et al, "Novel Fucolipids Accumulating in Human Adenocarcinoma", pages 4681-4685, see entire document.	1-8,10-11 40-42, 44-54, 56-65, 90 & 92-93
Y	The Journal of Biological Chemistry, Vol. 259, no. 16, issued 25 August 1984, Y. Fukushi et al. "Novel Fucolipids Accumulating in Human Adenocarcinoma", pages 10511-10517, see entire document.	1-8,10-11 40-42, 44-54, 56-65, 90 & 92-93
<p>* Special categories of cited documents: ¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"A" document member of the same patent family</p>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
21 September 1991	08 OCT 1991	
International Searching Authority	Signature of Authorized Officer	
ISA/US	<i>Nancy S. Carson</i> Nancy S. Carson ebw	

International Application No. PCT/US91/03592

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

V. ☐ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE¹

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☐ Claim numbers _____, because they relate to subject matter ¹² not required to be searched by this Authority, namely:

2. ☐ Claim numbers _____, because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out ¹³, specifically:

3. ☐ Claim numbers _____, because they are dependent claims not drafted in accordance with the second and third sentences of PCT Rule 5.4(a).

VI. ☒ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING²

This international Searching Authority found multiple inventions in this international application as follows:

See attached sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.
2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:
3. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:
1-8, 10-11, 40-42, 44-54, 56-65, 90, 92 and 93
4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the international Searching Authority did not invite payment of any additional fee.

Remark on Protest

- ☐ The additional search fees were accompanied by applicant's protest.
☐ No protest accompanied the payment of additional search fees.

International Application No.

PCT/US91/03592

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
Y	The Journal of Biological Chemistry. Vol. 260. no. 12. issued 25 June 1985. E.H. Holmes et al.. "Enzymatic Basis for the Accumulation of Glycolipids with X and Dimeric X Determinants in Human Lung Cancer Cells (NCI-H69)". pages 7619-7627, see entire document.	1-8,10-11,40-42, 44-54, 56-65,90 & 92-93
Y	The Journal of Biological Chemistry. Vol. 263. no. 23. issued 15 August 1988. P. Stanley et al. "The LEC11 Chinese Hamster Ovary Mutant Synthesizes N-linked Carbohydrates Containing Sialylated, Fucosylated Lactosamine Unites." pages 11374-11381, see entire document.	1-8,10-11,40-42, 44-54, 56-65,90 & 92-93
Y	Science. Vol. 243. issued 03 March 1989. M.P. Bevilacqua et al., "Endothelial Leukocyte Adhesion Molecule 1: An inducible Receptor for Neutrophils Related to Complement Regulation Proteins and Lectins". pages 1160-1165, see entire document.	1-8,10-11,40-42, 44-54, 56-65,90 & 92-93
Y,P	Science, Vol. 250, issued 23 November 1990, M.L. Phillips et al., "ELAM-1 mediates Cell Adhesion by Recognition of a Carbohydrate Ligand. Sialyl-Lex" pages 1130-1132, see entire document.	1-8,10-11,40-42, 44-54, 56-65,90 & 92-93
Y,P	Science, vol. 250, issued 23 November 1990. G. Walz et al., "Recognition by ELAM-1 of the Sialyl-Lex determinant on myeloid and tumor cells", pages 1132-1135, see entire document.	1-8,10-11,40-42, 44-54, 56-65,90 & 92-93

Serial No. PCT/US91/03592
Art Unit 183

-2-

Attachment to Form PCT/ISA/210 Part VI

Itemized summary of claims groupings

5 I. Claims 1-65 and 90-93, drawn to pharmaceutical compositions comprising compounds and a first method of using the compositions, classified in Class 424 subclass 85.8, Class 424 subclass 450, Class 514 subclass 8, Class 514 subclass 23, and Class 536 subclass 123.

10 There are independent and distinct species pertinent to the invention of Group I. The first named species, the moiety contains fucose and sialic acid and the compound is a polysaccharide (claims 4-8, 10, 11 and 90), will be searched to the extent that claims 1-65 and 90-93 embrace it. Note that a search of any other additional species within Group I requires payment of additional fees. The additional species are:

15 a) the compound is a glycopeptide or glycoprotein (claims 9, 27-32 and 91);

20 b) the compound is a glycolipid (claims 9, 19, 23, 24 and 91);

c) the composition comprises a liposome (claims 12-18 and 20-22);

d) the compound is heterocyclic (claims 25 and 26);

25 e) the composition comprises an immunoglobulin (claims 33-39).

II. Claims 66-75, drawn to a method of assaying a test compound for the ability to inhibit selectin-mediated cellular adhesion, classified in Class 424 subclass 85.8, Class 530 subclass 350 and Class 536 subclass 123.

30 There are independent and distinct species pertinent to the invention of Group II. The first named species, the agent comprises an SLX moiety, the receptor is on an activated endothelial cell, any of which may be labeled or immobilized (claims 66-70 and 72-75), will be searched to the extent that claims 66-75 embrace it upon payment of the requisite fee for Group II. Note that a search of any other additional species within Group II requires payment of additional fees. The additional species are:

40 f) the agent comprises an SLX mimetic (claim 67);

g) the agent comprises an immunoglobulin (claim 67);

h) the step of detecting is carried out by detecting physiological change in a cell (claim 71).

45 III. Claims 76-82, drawn to a method of assaying for the ability of an oligosaccharide moiety to selectively bind a selectin receptor, classified in Class 424 subclass 85.8, Class 536 subclass 123 and Class 530 subclass 350.

50 There are independent and distinct species pertinent to the invention of Group III. The first named species, the method

Serial No. PCT/US91/03592
Art Unit ~~187~~ 183

-3-

further comprises contacting the test compound with a selectin-binding agent wherein the agent is immunoglobulin (claims 80-81), will be searched to the extent that claims 76-82 embrace it upon payment of the requisite fee for Group III. Note that a search of any other additional species within Group III requires payment of additional fees. The additional species is
i) the agent is an SLX moiety (claim 82).

IV. Claims 83-89, drawn to a method of assaying a test compound for the ability to selectively bind an SLX moiety, classified in Class 536, subclass 123, Class 424 subclass 85.8 and Class 530 subclass 350.

There are independent and distinct species pertinent to the invention of Group IV. The first named species, the method further comprises contacting the test compound with an SLX-binding agent which is an immunoglobulin (claims 87-88), will be searched to the extent that claims 83-89 embrace it upon payment of the requisite fee for Group IV. Note that a search of any other additional species within Group IV requires payment of additional fees. The additional species is:
j) the SLX-binding agent is a selectin receptor (claim 89).

The inventions are distinct, each from the other because of the following reasons:

The process of Group I is materially distinct from the processes of Groups II, III and IV because the administration of a therapeutically effective dose is practiced with materially different process steps and has materially different purposes from the steps and purposes of testing compounds.

The inventions of Groups II, III and IV are distinct and independent each from the other as the claimed process steps are different, and the modes of detecting are different.

PCT Rules 13.1 and 13.2 do not provide for multiple distinct methods within a single general inventive concept.